# TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM644733

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

# **CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
KALA PHARMACEUTICALS, INC.		05/04/2021	Corporation:

## **RECEIVING PARTY DATA**

Name:	OXFORD FINANCE LLC
Street Address:	115 SOUTH UNION STREET, SUITE 300
City:	ALEXANDRIA
State/Country:	VIRGINIA
Postal Code:	22314
Entity Type:	Limited Liability Company: DELAWARE

## **PROPERTY NUMBERS Total: 24**

Property Type	Number	Word Mark
Registration Number:	4585580	KALA
Registration Number:	5401810	KALA
Registration Number:	5722929	INVELTYS
Serial Number:	87492692	VYSTALI
Serial Number:	87492700	LORPREXIO
Serial Number:	87492704	SUVEOUS
Serial Number:	87492707	VISOOVA
Registration Number:	6301667	EYSUVIS
Serial Number:	87694665	ZUDREYA
Serial Number:	87694667	SOODRYA
Registration Number:	5968321	INVELTYS
Registration Number:	5968322	INVELTYS
Registration Number:	5968323	V
Registration Number:	5968324	V
Serial Number:	88062537	ALMIENCE
Serial Number:	88062546	LUXTREON
Serial Number:	88062540	REYALBIS
Registration Number:	5951075	AMPPLIFY
Registration Number:	6310078	EYSUVIS
		TRÂDEMARK

**REEL: 007282 FRAME: 0798** 900614742

Property Type	Number	Word Mark
Registration Number:	6310079	EYSUVIS
Serial Number:	88797027	RELFLAYRA
Serial Number:	88797025	SPEDLYF
Serial Number:	90126591	EYSUVIS
Serial Number:	90126587	EYSUVIS

#### **CORRESPONDENCE DATA**

**Fax Number:** 6173106001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6173105234

Email: prezase@gtlaw.com
Correspondent Name: Eugenia A. Prezas
Address Line 1: Greenberg Traurig, LLP


Address Line 2: One International Place, Suite 2000
Address Line 4: Boston, MASSACHUSETTS 02110

NAME OF SUBMITTER:	Eugenia A. Prezas
SIGNATURE:	/Eugenia A. Prezas/
DATE SIGNED:	05/06/2021

### **Total Attachments: 76**

source=IPSecurityAgreementMay2021#page1.tif source=IPSecurityAgreementMay2021#page2.tif source=IPSecurityAgreementMay2021#page3.tif source=IPSecurityAgreementMay2021#page4.tif source=IPSecurityAgreementMay2021#page5.tif source=IPSecurityAgreementMay2021#page6.tif source=IPSecurityAgreementMay2021#page7.tif source=IPSecurityAgreementMay2021#page8.tif source=IPSecurityAgreementMay2021#page9.tif source=IPSecurityAgreementMay2021#page10.tif source=IPSecurityAgreementMay2021#page11.tif source=IPSecurityAgreementMay2021#page12.tif source=IPSecurityAgreementMay2021#page13.tif source=IPSecurityAgreementMay2021#page14.tif source=IPSecurityAgreementMay2021#page15.tif source=IPSecurityAgreementMay2021#page16.tif source=IPSecurityAgreementMay2021#page17.tif source=IPSecurityAgreementMay2021#page18.tif source=IPSecurityAgreementMay2021#page19.tif source=IPSecurityAgreementMay2021#page20.tif source=IPSecurityAgreementMay2021#page21.tif source=IPSecurityAgreementMay2021#page22.tif source=IPSecurityAgreementMay2021#page23.tif

source=IPSecurityAgreementMay2021#page24.tif source=IPSecurityAgreementMay2021#page25.tif source=IPSecurityAgreementMay2021#page26.tif source=IPSecurityAgreementMay2021#page27.tif source=IPSecurityAgreementMay2021#page28.tif source=IPSecurityAgreementMay2021#page29.tif source=IPSecurityAgreementMay2021#page30.tif source=IPSecurityAgreementMay2021#page31.tif source=IPSecurityAgreementMay2021#page32.tif source=IPSecurityAgreementMay2021#page33.tif source=IPSecurityAgreementMay2021#page34.tif source=IPSecurityAgreementMay2021#page35.tif source=IPSecurityAgreementMay2021#page36.tif source=IPSecurityAgreementMay2021#page37.tif source=IPSecurityAgreementMay2021#page38.tif source=IPSecurityAgreementMay2021#page39.tif source=IPSecurityAgreementMay2021#page40.tif source=IPSecurityAgreementMay2021#page41.tif source=IPSecurityAgreementMay2021#page42.tif source=IPSecurityAgreementMay2021#page43.tif source=IPSecurityAgreementMay2021#page44.tif source=IPSecurityAgreementMay2021#page45.tif source=IPSecurityAgreementMay2021#page46.tif source=IPSecurityAgreementMay2021#page47.tif source=IPSecurityAgreementMay2021#page48.tif source=IPSecurityAgreementMay2021#page49.tif source=IPSecurityAgreementMay2021#page50.tif source=IPSecurityAgreementMay2021#page51.tif source=IPSecurityAgreementMay2021#page52.tif source=IPSecurityAgreementMay2021#page53.tif source=IPSecurityAgreementMay2021#page54.tif source=IPSecurityAgreementMay2021#page55.tif source=IPSecurityAgreementMay2021#page56.tif source=IPSecurityAgreementMay2021#page57.tif source=IPSecurityAgreementMay2021#page58.tif source=IPSecurityAgreementMay2021#page59.tif source=IPSecurityAgreementMay2021#page60.tif source=IPSecurityAgreementMay2021#page61.tif source=IPSecurityAgreementMay2021#page62.tif source=IPSecurityAgreementMay2021#page63.tif source=IPSecurityAgreementMay2021#page64.tif source=IPSecurityAgreementMay2021#page65.tif source=IPSecurityAgreementMay2021#page66.tif source=IPSecurityAgreementMay2021#page67.tif source=IPSecurityAgreementMay2021#page68.tif source=IPSecurityAgreementMay2021#page69.tif source=IPSecurityAgreementMay2021#page70.tif source=IPSecurityAgreementMay2021#page71.tif



#### INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of May 4, 2021 by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 ("Oxford"), as collateral agent (in such capacity, "Collateral Agent"), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a "Lender" and collectively, the "Lenders"), and KALA PHARMACEUTICALS, INC., a Delaware corporation with an address at 490 Arsenal Way, Suite 120, Watertown, MA 02472 ("Grantor").

#### RECITALS

- A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Borrower (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement;" capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Borrower, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.
- B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

#### **AGREEMENT**

To secure its obligations under the Loan Agreement and other Loan Documents (as defined in the Loan Agreement), Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits  $\underline{A}$ ,  $\underline{B}$  and  $\underline{C}$  hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or

hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

KALA PHARMACEUTICALS, INC.

490 Arsenal Way
Suite 120
Watertown, MA 02472
Attn: Mary Reumuth, Chief Financial
Officer

COLLATERAL AGENT:

Address of Lender:

OXFORD FINANCE LLC

Name:

Title:\_\_\_\_\_

Suite 300

Alexandria, VA 22314

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly

[Signature Page to IP Security Agreement]

**GRANTOR:** Address of Grantor: KALA PHARMACEUTICALS, INC. 490 Arsenal Way Suite 120 By:\_\_\_ Watertown, MA 02472 Name: Attn: Mary Reumuth, Chief Financial Title: Officer **COLLATERAL AGENT:** OXFORD FINANCE LLC Address of Lender: 115 South Union Street Name: Colette H. Featherly Suite 300 Title: Senior Vice President Alexandria, VA 22314

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly

executed by its officers thereunto duly authorized as of the first date written above.

# EXHIBIT A

Copyrights

None.

# EXHIBIT B

Patents

(See attached.)

# OUR REF NO Assignee John's Hopkins University (JHU) In-licensed from JHU TITLE(S) JIL001 A SPEC = SURFACE MODIFICATION OF PARTICLES JIL001 B SPEC = DRUGS AND GENE CARRIER PARTICLES THAT RAPIDLY MOVE THROUGH MUCOUS BARRIERS JIL001 C SPEC = DRUGS AND GENE CARRIER PARTICLES THAT RAPIDLY MOVE THROUGH MUCOUS BARRIERS PATENT FAMILY: JIL001 JIL001.C/US JIL001.C/WO JIL001.B/USPR JIL001.A/USPR JIL001.C/US2 JIL001.C/EP (United States) [Pub'd as US 2016/0256404 [Pub'd as EP1713514 on 25-[Pub'd as US 2008/0166414 [Pub'd as WO 2005/072710 APPL'N NO & COUNTRY (European Patent Office) PCT/US2005/002556 on 11-Aug-2005] on 8-Sep-2016] (United States) (United States) (United States) on 10-Jul-2008 05722577.3 (PCT Int'll) 60/579,533 60/539,773 14/620,333 10/587,512 FILING DATE 28-Jan-2005 28-Jan-2005 28-Jan-2004 12-Feb-2015 8-Nov-2007 14-Jun-2004 (371 Date) DIV of JIL001.C/US Nat'l Stage of JIL001.C/WO JIL002.B Provisional 2 Provisional 1 FAMILY REL'P Nat'l Stage of JIL001.C/WO PCT of Provisionals JIL002.A & US 8,957,034 on 17 Feb-2015 PATENT NO & ISSUE DATE ISSUED PENDING (Allowed) EXPIRED/ IN NATIONAL STAGE **EXPIRED EXPIRED** STATUS ABANDONED

PATENT FAMILY: JIL002					
TITLE(S): COMPOSITIONS AND	TITLE(S): COMPOSITIONS AND METHODS FOR ENHANCING TRANSPORT THROUGH MUCUS	NSPORT THROUGH MUCUS			
Assignee. John's Hopkins University (JHU) In-licensed from JHU	SW) (JHU)				
OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
JIL002.A/USPR	60/843,282 (United States)	8-Sep-2006	Provisional		EXPIRED
JIL002.B/WO	PCT/US2007/019522 (PCT Intil) [Pub'd as WO2008/030557 on13-Mar-2008]	7-Sep-2007	PCT of JIL002.A/USPR		EXPIRED/ IN NATIONAL STAGE
JIL002.B/AU	2007/292902 (Australia) [Pub'd as AU2007292902 on 13-Mar-2008]	7-Sep-2007	Nat'l Stage of JIL002.BWO	AU 2007292902 on 05-Dec- 2013	GRANTED
JIL002.B/AU2	2013/257518 (Australia)	7-Sep-2007	DIV of JIL002.B/AU		ABANDONED
JIL002.B/CA	2,663,003 (Canada) [Pub'd as CA2663003 on 13- Mar-2008]	7-Sep-2007	Nat'l Stage of JIL002.BWO	CA2663003 on 13-Feb-2018	GRANTED
JIL002.B/EP	07837876.7 (European Patent Office)	7-Sep-2007	Nat'l Stage of JIL002.B/WO	EP2061433 B1 on 02/16/2011	REVOKED on Appeal of Opposition by Vectura Ltd.

JIL001.C/US4	JIL001.C/US3
17/012,976 (United States)	15/988,615 (United States) [Pub'd as US 2018/0344656 on -Dec2018
04-Sep-2020	24-May-2018
DIV of JIL001.C/US3	CON of JIL001.C/US2
PENDING	Abandoned

JIL002.B/US5	JIL002.B/US4	JIL002.B/US3	JIL002.B/US2	JIL002.B/US	JIL002.B/JP3	JIL002.B/JP2	JIL002.B/JP	JIL002.B/HK-EP	
16/936,220 (United States)	15/982,447 (United States) [Pub'd as US2018/0264135 on 20-Sep-2018]	15/196,178 (United States) [Pub'd as 2017/0095566 on 06-Apr-2017]	13/692,442 (United States) [Pub'd as US 2013/0164343 on 27-Jun-2013]	12/310,751 (United States) [ Pub'd as US 2010/0215580 on 26-Aug-2010]	2014-256,264 (Japan) [Pub'd as JP201557438 on 26-Mar-2015]	2013-110,583 (Japan) [Pub'd as JP2013163697 on 22-Aug-2013]	2009-527,422 (Japan) [Pub'd as JP2010502713 on 28-Jan-2010]	09110690.3 (Hong Kong)	[Pub'd as EP2061433 on 27- May-2009]
22-Jul-2020	17-May-2018	29-Jun-2016	3-Dec-2012	22-Jan-2010 (371 Date)	7-Sep-2007	7-Sep-2007	7-Sep-2007	7-Sep-2007	
DIV of JIL002.B/US4	CON of JIL002.B/US3	CON of JIL002.B/US2	CON of JIL002.B/US	Nat'l Stage of JIL002.B/WO	DIV of JIL002.B/JP2	DIV of JIL002.B/JP	Nat'l Stage of JIL002.B/WO	HK Registration of JIL002.B/EP	
					JP6297481 on 02-Mar-2018				
PENDING	ABANDONED	ABANDONED	ABANDONED	ABANDONED	GRANTED	ABANDONED	ABANDONED	Registered EP - Revoked with JIL002.B/EP	

### OUR REF. NO Assignee John's Hopkins University (JHU) In-licensed from JHU TITLE(S): COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION PATENT FAMILY: JIL003 JIL003.B/CA JIL003.B/AU JIL003.B/WO JIL003.B/US4 JIL003.B/US2 JIL003.B/US JIL003.A/USPR JIL003.B/US3 (United States) [Pub'd as US 2017/0007542 (United States) [Pub'd as US2012/0121718 (United States) [Pub'd as US2013/0236556 [Pub'd as CA2816977 on 12-[Pub'd as AU2011323250 on [Pub'd as WO2012/061703 APPLINIO & COUNTRY PCT/US2011/059321 on 10-May-2012] on 12-Sep-2013] 15/065,017 on 17-May-2012] (United States) 02-May-2013] on 12-Jan-2017] (United States) May-2012] 2011/323250 61/410,539 (Australia) (Canada) 16/510,355 13/853,406 13/289,196 2,816,977 (PCT Int'll) FILING DATE 29-Mar-2013 4-Nov-2011 4-Nov-2011 4-Nov-2011 9-Mar-2016 4-Nov-2011 11/5//2010 FAMILY REL'P Nat'l Stage of JIL003.B/WO Nat'l Stage of JIL003.B/WO PCT of JIL003.A/USPR CON of JIL003.B/US3 CON of JIL003.B/US2 CON of JIL003.B/US US ORD of JIL003.A/USPR Provisional AU2011323250 on 03-Mar-2016 PATENT NO & ISSUE DATE CA2816977 on 29-Oct-2019 GRANTED GRANTED EXPIRED/ IN NATIONAL STAGE ABANDONED **ABANDONED** STATUS PENDING EXPIRED ABANDONED

JIL004.B/WO	JIL004,A/USPR	OUR REF. NO	Assignee: John's Hopkins University (JHU) In-licensed from JHU	TITLE(S): RAPID DIFFUSION	PATENT FAMILY: JIL004
PCT/US2011/051195 (PCT Int'l) [Pub'd as WO2012/039979 on 29-Mar-2012]	61/381,754 (United States)	APPLIN NO. & COUNTRY	ersity (JHU)	TITLE(S): RAPID DIFFUSION OF LARGE POLYMERIC NANOPARTICLES IN THE MAMMALIAN BRAIN	
12-Sep-2011	10-Sep-2010	FILING DATE		TICLES IN THE MAMMALIAN BRAIN	
PCT of JIL004,A/USPR	Provisional 1	FAMILY REL'P		4	
		PATENT NO. & ISSUE DATE			
EXPIRED/ IN NATIONAL STAGE	EXPIRED	STATUS			

JIL003.B/HK-EP	JIL003.B/EP-UK	JIL003.B/EP-FR	JIL003.B/EP-DE	JIL003.B/EP	JIL003.B/CA2
13110775.5 (Hong Kong) [Pub'd as HK1183433 on 27- Dec-2013]	(Great Britain)	(France)	(Germany)	11838873.5 (European Patent Office) [Pub'd as EP2635254 on 11- Sep-2013]	3,054,532 (Canada)
4-Nov-2011	4-Nov-2011	4-Nov-2011	4-Nov-2011	4-Nov-2011	4-Nov-2011
HK Registration of JIL003.B/EP	Validation of JIL003.B/EP	Validation of JIL003.B/EP	Validation of JIL003.B/EP	Nat'l Stage of JIL003.B/WO	DIV of JIL003.B/CA
				EP2635254 on 15-May-2019	
ABANDONED				GRANTED	PENDING

PATENT FAMILY: JIL005					
TITLE(S) JIL005.A SPEC NA JIL005.B SPEC MI JIL005.F SPEC NA JIL005.G SPEC NA	JILDOS A SPEC NANOPARTICLES WITH ENHANCED MUCOSAL PENETRATION OR DECREASED INFLAMMATION JILDOS B SPEC MUCUS PENETRATING GENE CARRIERS JILDOS F SPEC NANOPARTICLES WITH ENHANCED MUCOSAL PENETRATION OR DECREASED INFLAMMATION JILDOS G SPEC NANOPARTICLE FORMULATIONS WITH ENHANCED MUCOSAL PENETRATION	UCOSAL PENETRATION OR DECR RS UCOSAL PENETRATION OR DECR TENHANCED MUCOSAL PENETRA	EASED INFLAMMATION EASED INFLAMMATION TION		
Assignee: John's Hopkins University (JHU) In-licensed from JHU	rsity (JHU)				
OUR REF NO	APPL'N NO & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO & ISSUE DATE	STATUS
JIL005.A/USPR	61/431,521 (United States)	11-Jan-2011	Provisional 1		EXPIRED
JIL005.B/USPR	61/440,647 (United States)	8-Feb-2011	Provisional 2		EXPIRED
JIL005.B/WO	PCT/US2012/024344 (PCT Int'l) [Pub'd as WO2012/109363	8-Feb-2012	PCT of JIL005.B/USPR		EXPIRED/ IN NATIONAL STAGE
JIL005.B/US	13/984,386 (United States) [Pub'd as US2013/0323313 on 05-Dec-2013]	8-Aug-2013 (371 Date)	Nat'l Stage of JIL005.BWO	US 9,327,037 on 03-May-2016	ISSUED
JIL005.B/US2	15/144.077 (United States) [Pub'd as US2016/0243257 on 25-Aug-2016]	2-May-2016	CON of JIL005.B/US	US 9,675,711 on 13-Jun-2017	ISSUED
JIL005.B/US3	15/592,383 (United States) [Pub'd as US2017/0246320 on 31-Aug-2017]	11-May-2017	CON of JIL005.B/US2	US10,729,786 on 04-Aug-2020	ISSUED
	•				

_004.B/US	13/821,320	7-Mar-2013	Nat'l Stage of JIL004.B/WO	US 10,307,372 on 04-Jun-2019	ISSUED
	(United States)	(371 Date)			
	[Pub'd as US2013/0183244				
	on 18-Jul-2013]				

JIL005.F/EP-FR	JIL005.F/EP-DE	JIL005.F/EP	JIL005.F/CN	JIL005.F/CA	JIL005.F/AU2	JIL005.F/AU	JIL005.F/WO	JIL005.E/USPR	JIL005.D/USPR	JIL005.C/USPR
(France)	(Germany)	12820997.0 (European Patent Office) [Pub'd as EP2790733 on 22- Oct-2014]	201280069271.1 (China) [Pub'd as CN104105507 on 15-Oct-2015]	2,859,046 (Canada) [Pub'd as CA2859046 on 20- Jun-2013]	2016/200683 (Australia) [Pub'd as AU2016200683 on 18-Fed-2016]	2012/351994 (Australia) [Pub'd as AU2012351994 on 24-Jul-2014]	PCT/US2012/069882 (PCT Int'I) [Pub'd as WO2013/090804 on 20-Jun-2013]	61/588,350 (United States)	61/570,413 (United States)	61/570,405 (United States)
		14-Dec-2012	14-Dec-2012	14-Dec-2012	14-Dec-2012	14-Dec-2012	14-Dec-2012	19-Jan-2012	14-Dec-2011	14-Dec-2011
Validation of JIL005,F/EP	Validation of JIL005,F/EP	Nat'l Stage of JIL005.F/WO	Nat'l Stage of JIL005.F/WO	Nat'l Stage of JIL005.F/WO	DIV of JIL005.F/AU	Nat'l Stage of JIL005.F/WO	PCT of JIL005.C/USPR, JIL005.D/USPR, & JIL005.B/WO	Provisional 5	Provisional 4	Provisional 3
		EP2790733 on 30-Oct-2019	CN104105507 on 2-Mar-2020	CA2859046 on 22-Oct-2019	AU2016200683 on 23-Nov- 2017	AU2012351994 on 18-Feb-2016				
		GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	EXPIRED/ IN NATIONAL STAGE	EXPIRED	EXPIRED	EXPIRED

JIL005.F/EP-GB	(Great Britain)	44 55 44000	Validation of JIL005.F/EP		
JIL005.F/HK-CN	15103577.8 (Hong Kong) [Pub'd as HK1203052 on 16- Oct-2015]	14-Jan-1900	HK Registration of JIL005.F/CN		REGISTERED
JIL005.F/JP	2014-547513 (Japan) [Pub'd as JP2015505855 on 26-Feb-2015]	14-Dec-2012	Nat'l Stage of JIL005.F/WO	JP6308679 on 23-Mar-2018	GRANTED
JIL005.F/JP2	2016-78766 (Japan) [Pub'd as JP2016128522 on 14-jul-2016]	14-Dec-2012	DIV of JIL005.FJP	JP6590750 on 27-Sep-2019	GRANTED
JIL005.F/JP3	2018-17235 (Japan) [Pub'd as JP2018065882 on 26-Apr-2018]	12-Dec-2012	DIV of JIL005.F/JP		PENDING (Published)
JIL005.F/KR	10-2014-7019535 (South Korea)	14-Dec-2012	Nat'l Stage of JIL005.F/WO		ABANDONED
JIL005.F/RU	2014128578 (Russian Federation) [Pub'd as RU2014128578 on 10-Feb-2016]	14-Dec-2012	Nat'l Stage of JIL005.F/WO	RU2631599 on 25-Sep-2017	GRANTED
JIL005.F/US	14/365,963 (United States) [Publ'd as US2014/0329913 on 06-Nov-2014]	16-Jun-2014 (371 Date)	Nat'l Stage of JIL005.F/WO		ABANDONED
JIL005.F/US2	17/184,087 (United States)	24-Feb-2021	CON of JIL005, F/US		PENDING
JIL005.G/WO	PCT/US2013/022387 (PCT Int1) [Publ'd as WO2013/110028 on 25-Jul-2013]	21-Jan-2013	PCT of JIL005.E/USPR & JIL005.E/WO & JIL005.F/WO		EXPIRED/IN NATIONAL STAGE
JIL005.G/AU	2013/209452 (Australia) [Pub'd as AU2013209452 on 28-Aug-2014]	21-Jan-2013	Nat'l Stage of JIL005.G/WO	AU2013209452 on 18-Feb-2016	GRANTED

21-Jan-2013       Nat'l Stage of JIL005.G/WO       KR 10-11811917(B1) on 22-Dec-2017         21-Jan-2013       Nat'l Stage of JIL005.G/WO       RU2598627 on 27-Sep-2016
KR 10-11811917(B1) on 22- Dec-2017 RU2598627 on 27-Sep-2016
Dec-2017
Nat'l Stage of JIL005.G/WO

PATENT FAMILY: JIL006					
TITLE(S) LIPID-BASED DRUG	TITLE(S) LIPID-BASED DRUG CARRIERS FOR RAPID PENETRATION THROUGH MUCUS LININGS	ON THROUGH MUCUS LININGS			
Assignee. John's Hopkins University (JHU) In licensed from JHU	SMY (JHU)				
OUR REF NO	APPLINING & COUNTRY	FILING DATE	FAMILY RELIP	PATENT NO. & ISSUE DATE	STATUS
JIL006.A/USPR	61/642,776 (United States)	4-May-2013	Provisional 1		EXPIRED
JIL006.B/WO	PCT/US2013/039731 (PCT Intil) IPub'd as WO2013/166498	6-May-2013	PCT of JIL006.A/USPR		EXPIRED/ IN NATIONAL STAGE
	ON U/-NOV-2013]				
JIL006.B/AU	2013/256008 (Australia)	6-May-2013	Nat'l Stage of JIL006.B/WO	AU2013256008 on 9-Jun-2016	GRANTED
	[Pub'd as AU2013256008 on 20-Nov-2014]				
JIL006.B/CA	2,872,519 (Canada)	6-May-2013	Nat'l Stage of JIL006.B/WO	CA2872519 on 5-Sep-2017	GRANTED
	[Pub'd as CA2872519 on 07- Nov-2013]				
JIL006.B/EP	13722265.9	6-May-2013	Nat'l Stage of JIL006.B/WO		PENDING (Published)
	(European Patent Office) [Pub'd as EP2849728 on 25- Mar-2015]				
JIL006.B/HK-EP	15109178.8	6-May-2013	HK Registration of JIL006.B/EP		PENDING (Published)
	(Hong Kong) [Pub'd as HK1208377 on 04-				
	Mar-2016]				

(PCT Intl) [Pub'd as WO2017/075565 on 04-May-2017]	PATENT FAMILY: JIL008  TITLE(S): MUCUS PENETRATING PART  Assignee. John's Hopkins University (JHU) In-licensed from JHU  CUR REF. NO  JIL008.A/USPR	3 PARTICLES WITH HIGH MOLEC  Y (JHILI)  APPLIN NO. & COUNTRY  62/248,432 (United States)	PATENT FAMILY: JIL008  HTLE(S), MUCUS PENETRATING PARTICLES WITH HIGH MOLECULAR WEIGHT AND DENSE COATINGS Assignee: John's Hopkins University (JHU) In-licensed from JHU  OUR REF: NO  APPL'N NO. & COUNTRY  FILING DATE  FJ  JIL008.A/USPR  62/248,432 (United States)  POT 1004.0566664  POT 1004.666664  POT 1004.666644  POT 1004.6666444  POT 1004.66664444  POT 1004.66664444  POT 1004.666644444  POT 1004.666444444444  POT 1004.66644444444444444444444444444444444	FAMILY RELP Provisional 1	PATENT NO. & ISSUE DATE	STATUS
31-Oct-2016 PCT of JIL008.A/USPR	JIL008,A/USPR	62/248,432 (United States)	30-Oct-2015	Provisional 1		EXPIRED
	JIL008.B/WO	PCT/JS2016/059661 (PCT Intil) [Pub'd as WO2017/075565 on 04-May-2017]	31-Oct-2016	PCT of JIL008.A/USPR		EXPIRED/ IN NATIONAL STAGE

<b>JIL006.B/US2</b> (U [Pub'd: on	JIL006.B/US (U [Pub'd ax on	JIL006.B/JP2 [Pub'd	JIL006.B/JP [Pub'd
15/890,156 (United States) [Pub'd as US2018/0169263 on 21-Jun-2018]	14/397,828 (United States) [Pub'd as US2015/0086484 on 26-Mar-2015]	2017-220782 (Japan) [Pub'd as JP201839836 on 15-Mar-2018]	2015-510507 (Japan) [Pub'd as JP201515992 on 04-Jun-2015]
6-Feb-2018	29-Oct-2014 (371 date)	6-May-2013	6-May-2013
CON of JIL006.B/US	Nat'l Stage of JIL006.B/WO	DIV of JIL006.B/JP	Nat'l Stage of JIL006.B/WO
US 10,556,017 on 11-Feb-2020	US 9,889,208 on 13-Feb-2018		JP6392209 on 31-Aug-2018
ISSUED	ISSUED	ABANDONED	GRANTED

JIL009.B/US2	JIL009.B/US	JIL009,A/PROV		Assignee. John's Hopkins University (JHU) In-licensed from JHU	TITLE(S) MUCUS-PENETRATING BUDESONIDE NANOSUSPENSION ENEMA FOR LOCAL TREATMENT OF INFLAMMATORY E	PATENT FAMILY: JIL009
16/828,222 (United States) [Pub'd as US2020/0306202 on 01-Oct-2020]	16/036,819 (United States) [Pub'd as US2019/0015349 on 17-Jan-2019)	62/532,883 (United States)	APPL'N NO. & COUNTRY	HUJ	JDESONIDE NANOSUSPENSION E	
24-Mar-2020	16-Jul-2018	14-Jul-2017	FILING DATE		ENEMA FOR LOCAL TREATMENT	
CON of JIL009.B/US	Non-provisional of JIL009,A/PROV		FAMILY RELP		OF INFLAMMATORY BOWEL DISEASE	
			BATEM NO. 8 INSTAR		SEASE	
PENDING	ABANDONED	EXPIRED	STATUS			

GBS01.D/US	GBS01.D/EP	GBS01.D/CA	GBS01.D/WO	GBS01.C/USPR	GBS01.B/USPR	GBS01.A/USPR	OUR REF. NO APPL'N NO. & COUNTRY	PATENT FAMILY: GBS01  TITLE(S): SUSTAINED DELIVERY OF TH  Assignee: John's Hopkins University (JHU) Sublicensed from GrayBug LLC (now Gray
13/581,454 (United States) [Pub'd as US2012/0321719 on 20-Dec-2012]	11748181.2 (European Patent Office) [EP2538929A2 on 02-Jan-2013]	2,791,278 (Canada) [Pub'd as CA2791278 on 01- Sep-2011]	PCT/US2011/026321 (PCT Int!) [Pub'd as WO2011/106702 on 01-Sep-2011]	61/308,053 (United States)	61/308,402 (United States)	61/308,035 (United States)	APPL'N NO. & COUNTRY	PATENT FAMILY: GBS01  TITLE(S) SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT  Assignee John's Hopkins University (JHU) Sublicensed from GrayBug LLC (now Graybug Vision, Inc.)
8/27/2012 (371 Date)	25-Feb-2011	25-Feb-2011	25-Feb-2011	25-Feb-2010	25-Feb-2010	25-Feb-2010	FILING DATE	AN EYE COMPARTMENT
Nat'l Stage of GBS01.D/WO	Nat'l Stage of GBS01.D/WO	Nat'l Stage of GBS01.D/WO	PCT of GBS01.A, .B, & .C/USPR	Provisional 3	Provisional 2	Provisional 1	FAMILYRELP	
US 8,889,193 on 18-Nov-2014		CA2791278 on 24-Nov-2015					PATENT NO & ISSUE DATE	
ISSUED	PENDING (Published)	GRANTED	EXPIRED/ IN NATIONAL STAGE	EXPIRED	EXPIRED	EXPIRED	STATUS	

PATENT FAMILY: GBS02					
TITLE(S) GBS02.C SPEC CO	GBS02.0 SPEC_CONTROLLED RELEASE FORMULATIONS FOR THE DELIVERY OF HF-1 INHIBITORS GBS02.D SPEC_NON-LINEAR MUTLIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTS	INS FOR THE DELIVERY OF HIF-1	INHIBITORS E DELIVERY OF ACTIVE AGENTS		
Assignee John's Hopkins University (JHU) Sublicensed from GrayBug LLC (now Graybug Vision, Inc.)	ssty (JHU) (now Graybug Vision, Inc.)				
OUR REF NO	APPLINING & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
GBS02.A/USPR	61/611,931 (United States)	16-Mar-2012	Provisional 1		EXPIRED
GBS02.B/USPR	61/611,975 (United States)	16-Mar-2012	Provisional 2		EXPIRED
GBS02.C/US	13/797,506 (United States) [Pub'd as US2013/0274217 on 17-Oct-2013]	12-Mar-2013	US ORD Filing of GBS02.A/USPR	US 8,962,577 on 24-Feb-2015	ISSUED

GBS01.D/US2	14/521,904 (United States)	23-Oct-2014	CON of GBS01.D/US	US 9,566,242 on 14-Feb-2017
	[Pub'd as US2015/0044270			
	on 15-Feb-2015)			
GBS01.D/US3	15/138,132	25-Apr-2016	CON of GBS01.D/US2	US 9,937,130 on 10-Apr-2018
	(United States)			
	[Pub'd as US 2016/0235674			
	on 18-Aug-2016)			
GBS01.D/US4	15/884,158	30-Jan-2018	CON of GBS01.D/US3	US10,369,107 on 18-Aug-2019
	(United States)			
	[Pub'd as US 2018/0161277			
	on 14-Jun-2018)			
GBS01.D/US5	16/502,359	03-Jul-2019	CON of GBS01.D/US4	
	(United States)			
	[Pub'd as US2019/0321297			
	on 24-Oct-2019]			

GBS02.C/HK-EP 15106964.2 12-Mar-2013 (Hong Kong) [Pub'd as HK1206270 on 08-Jan-2016]	GBS02,C/EP-GB	GBS02.C/EP-FR	GBS02.C/EP-DE	GBS02.C/EP 13711263.7 12-Mar-2013 (European Patent Office) [Pub'd as EP2825206 on 21- Jan-2015]	GBS02.C/EA 2014-91710 12-Mar-2013 (Eurasian Patent Organization) [Pub'd as EA201491710 on 30-Apr-2015]	GBS02.C/CN 2013-80025514.6 12-Mar-2013 (China) [Pub'd as CN104363924 on 18-Feb-2015]	GBS02.C/CA 2,867,381 12-Mar-2013 (Canada) [Pub'd as CA 2867381 on 19-Sep-2013]	GBS02.C/AU       2013/232297       12-Mar-2013         (Australia)       [Pub'd as AU2013232297 on 23-Oct-2014]	GBS02.C/WO PCT/US2013/030533 12-Mar-2013  (PCT Int'l)  [Pub'd as WO2013/138343  on 19-Sep-2013]	GBS02.C/US2 14/599,853 19-Jan-2015  (United States)  [Pub'd as US2015/0141359  on 21-May-2015]
3 HK Registration of GBS02.C/EP	Validation of GBS02.C/EP	Validation of GBS02.C/EP	Validation of GBS02.C/EP	Nat'l Stage of GBS02.C/WO	Nat'l Stage of GBS02.C/WO	Nat'l Stage of GBS02.C/WO	Nat'l Stage of GBS02.C/WO	Nat'l Stage of GBS02.C/WO	PCT of GBS02.A/USPR	CON of GBS02.C/US
				EP2825207 on 19-Aug-2020	EA032552 on 28-Jun-2019	CN104363924 on 17-Apr-2018	CA 2,867,381 on 20-Sep-2016	AU2013232297 on 28-Apr-2016		US 9,950,072 on 24-Apr-2018
PENDING (Published)				GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	EXPIRED/IN NATIONAL STAGE	ISSUED

PATENT FAMILY: GBS03					
TITLE(S) GBS03A SPEC GLUCOCORT GBS03B SPEC GLUCOCOR GBS03C SPEC GLUCOCOR Assignee John s Hopkins University (JHU)	GBS03.4 SPEC. CLUCOCORTICOID LOADED NANOPARTICLES FOR PREVENTIONOF CORNEAL ALLOGRAFT REJECTION GBS03.8 SPEC. GLUCOCORTICOID LOADED NANOPARTICLES FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTIOI GBS03.C SPEC. GLUCOCORTICOID LOADED NANOPARTICLES FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTIOI John's Hopkins University (JHU)	TICLES FOR PREVENTIONOF CONTICLES FOR PREVENTION OF CONTIC	ORNEAL ALLOGRAFT REJECTION ORNEAL ALLOGRAFT REJECTION ORNEAL ALLOGRAFT REJECTION	EJECTION REJECTION AND NEOVASCULARIZATION REJECTION AND NEOVASCULARIZATION	
OUR REF NO	APPLINIO & COUNTRY	FILING DATE	FAMILYRELP	PATENT NO & ISSUEDATE	STATUS
GBS03.A/USPR	62/037,000 (United States)	13-Aug-2014	Provisional 1		EXPIRED
GBS03.B/USPR	62/139,561 (United States)	27-Mar-2015	Provisional 2		EXPIRED
GBS03.C/WO	PCT/US2015/043478 (PCT Int'l) [Pub'd as WO2016/025215 on 18-Feb-2016]	3-Aug-2015	PCT of GBS03.A/USPR & GBS03.B/USPR		EXPIRED/ IN NATIONAL STAGE
GBS03.C/CA	2,957,764 (Canada) [Pub'd as CA2957764 on 13- Aug-2014]	3-Aug-2015	Nat'l Stage of GBS03.C/WO	CA 2957764 on -2 Jul 2019	GRANTED

GBS02.D/EP	13712059.8 (European Patent Office) [Pub'd as EP2825207 on 21-	12-Mar-2013	Nat'l Stage of GBS02.DWO		PENDING (Published)
GBS02.D/HK-EP	15106961.5 (Hong Kong) [Pub'd as HK 1206268 on 08- Jan-2016]	12-Mar-2013	HK Registration of GBS02.D/EP		PENDING (Published)
GBS02.D/JP	2015-509986 (Japan)	12-Mar-2013	Nat'l Stage of GBS02.D/WO	JP6138904 on 31-May-2017	GRANTED

GBS05.A/USPR 62/092,118 15-Dec-2014 Provisional 1	GRS05 R/USDR 62/139 306 27-Mar-2015 Provisional 2	(United States)	GBS05.C/WO PCT/US2015/065878 15-Dec-2015 PCT1 of GBS05.A & .B/USPR (PCT Intl) [Pub'd as WO2016/100380 on 23-Jun-2016]	15/536 373 12 Doc 2015 Not!! Store of CBS05 CAAIO	360750	(United States)  [Pub'd as US2017/0360750 on 21-Dec-2017] 2
					US 10,525,034 on 07-Jan-2020	US 10,525,034 on 07-Jan-2020
	EXPIRED	EXPIRED	EXPIRED	EXPIRED  EXPIRED  EXPIRED/ N NATIONAL  STAGE	EXPIRED  EXPIRED/ N NATIONAL  STAGE  ISSUED	EXPIRED  EXPIRED N NATIONAL STAGE  ISSUED  PENDING

OJONE OILD	150011001	40 D>> 004F	חושות סלאייי של טם סטע טאוט		יייייייייייייייייייייייייייייייייייייי
GDGGG, CVT-T	(Europe) (Europe) [Pub'd as EP3233058 on 25- Oct-2017]	17-Dac-5019	THAT I DIGGE OF SECTION OF SECTIO		L ENDING (Laminilar)
GBS05.C/HK-EP	18103515.0 (Hong Kong) [Pub'd as HK1243942 on 27-		HK Registration of GBS05.C/EP		PENDING (Published)
GBS05.C/JP	2017-550467	12-Dec-2015	Nat'l Stage of GBS05.C/WO		PENDING (Published)
	(Japan) [Pub'd as JP2018500394 on 11-Nov-2018]				
GBS05.D/WO	PCT/US2015/065894	15-Dec-2015	PCT2 of GBS05.A &.B/USPR		EXPIRED/ IN NATIONAL
	(PCT int'l) [Pub'd as WO2016/100392 on 23-Jun-2016]				STAGE
GBS05.D/US	15/032,986 (United States)	28-Apr-2016	US Nat'l of GBS05.D/WO		PENDING (Published)
	on 28-Sep-2017]				
GBS05.D/US2	16/357,195	18-Mar-2019	CON of GBS05.D/US		PENDING (Published)
	(United States) [Pub'd as US2019/0275001 on 12-Sen2019]				
GBS05.D/AE	P6000725/2017	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING
	(United Arab Emirates)				
GBS05.D/AU	2015362621	15-Dec-2015	Nat'l Stage of GBS05.D/WO	2015362621 on 02-May-2019	GRANTED
	(Australia) [Pub'd as AU2015362621 on 13-Jul-2017]				
GBS05.D/BR	BR1120170127067	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING (Published)
	(Brazil) [Pub'd as BR112017012706 on 13-Mar-2018]				
GBS05.D/CA	2,972,075	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING (Published)
	(Canada) [Pub'd as CA2972075 on 23- .lun-2016]				
GBS05.D/CN	201580074390.X	15-Dec-2015	Nat'l Stage of GBS05.D/WO		PENDING (Published)
	(Crinna) [Pub'd as CN107205940 on 26 Sept-2017]				

PATENT FAMILY: KP001

| TITLE(6), FUNCTIONALIZED POLY(ETHER ANHYDRIDE) BLOCK COPOLYMERS

GBS05.D/SA	GBS05.D/RU	GBS05.D/QA	GBS05.D/OM	GBS05.D/MX	GBS05.D/JP	GBS05.D/IN	GBS05.D/IL	GBS05.D/HK-EP	GBS05.D/EP
517381718 (Saudi Arabia)	2017123358 (Russian Federation)	QA/201706/00267 (Qatar)	OM/P/2017/00171 (Oman)	MX/a/2017/007873 (Mexico) [Pub'd as MX2017007873 on 06-Nov-2017]	2017-550467 (Japan) [Pub'd as JP2017537985 on 21-Dec-2017]	201717024282 (India) [Pub'd as 41/2017 on 13-Oct- 2017]	252943 (Israel)	18100757.3 (Hong Kong) [Pub'd as HK1241281 on 08- Jun-2018]	15820019.6 (European Patent Office) [Pub'd as EP3233056 on 25- Oct-2017]
15-Dec-2015	15-Dec-2015	15-Dec-2015	15-Dec-2015	15-Dec-2015	15-Dec-2015	15-Dec-2015	15-Dec-2015		15-Dec-2015
Nat'l Stage of GBS05.D/WO	Nat'l Stage of GBS05.D/WO	Nat'l Stage of GBS05.D/WO	Nat'l Stage of GBS05.D/WO	Nat'l Stage of GBS05.D/WO	Nat'll Stage of GBS05.D/WO	Nat'l Stage of GBS05.D/WO	Nat'l Stage of GBS05.D/WO	HK Registration of GBS05.D/EP	Nat'l Stage of GBS05.D/WO
PENDING	PENDING	PENDING	PENDING	PENDING (Published)	PENDING (Published)	PENDING (Published)	PENDING	PENDING (Published)	PENDING (Published)

KP001.B/US	KP001.B/GB	KP001.B/FR	KP001.B/ES	KP001.B/DE	KP001.B/EP	KP001.B/CA	KP001.B/WO	KP001.A/USPR	OUR REF. NO	Assignee Kala
11/721,123 (United States) [Pub'd as US 2010/0003337 on 07-Jan-2010]	(Great Britain)	(France)	(Spain)	(Germany)	05853543.6 (European Patent Office) [ Pub'd as EP1856179 on 21- Nov-2017]	2,590,098 (Canada) [Pub'd as CA2590098 on 15- Jun-2006]	PCT/US2005/044658 (PCT Int'l) [Pub'd as WO 2006/063249 on 15-Jun-2006]	60/635,280 (United States)	APPLINING & COUNTRY	
9-Dec-2005(21-Sep-2009(371 Date))					9-Dec-2005	9-Dec-2005	9-Dec-2005	10-Dec-2004	FILING DATE	
Nat'l Stage of KP001.B/WO	Validation of KP001.B/EP	Validation of KP001.B/EP	Validation of KP001.B/EP	Validation of KP001.B/EP	Nat'l Stage	Nat'l Stage	PCT of KP001.A/USPR	Provisional	FAMILYRELP	
US 8,354,476 on 15-Jan-2013					EP1856179 on 15-May-2013	CA 2590098 on 31-Mar-2015			PATENT NO & ISSUE DATE	
ISSUED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	EXPIRED/ IN NATIONAL STAGE	EXPIRED	STATUS	

PATENT FAMILY: KP002 TITLE(S) COMPOSITIONS AND Assignee Kale	<b>PATENT FAMILY: KP002</b> TITLE(S): COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTIFIC Assignee, Kala	. ALCOHOL) AND/OR OTHER POLY		SLE TRANSPORT IN MUCUS	
OUR REF. NO	APPL'N NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP002.A/USPR	61/642,261 (United States)	3-May-2012	Provisional		EXPIRED
KP002.B/US	13/886,514 (United States) [ Pub'd as US 2013/0316009 on 28-Nov-2013]	3-May-2013	US ORD Filing of KP002.A/USPR	US10,668,041 on 23-Jun-2020	ISSUED
KP002.B/US2	16/883,778 (United States) [Pub'd as US2020/0289405 on 17-Sep-2020]	26-May-2020	DIV of KP002.B/US		PENDING
KP002.B/WO	PCT/US2013/039499 (PCT Int'l) [Pub'd as WO2013/166408 on 7-Nov-2013]	3-May-2013	PCT of KP002.A/USPR		EXPIRED/ IN NATIONAL STAGE
KP002.B/AU	2013/256064 (Australia) [Pub'd as AU2013256064 on 04-Jan-2018]	3-May-2013	Nat'l Stage of KP002.B/WO	AU2013256064 on 19-Apr-2018	GRANTED
KP002.B/AU2	2018202074 (Australia)	3-May-2013	DIV on KP002.B/AU	AU2018202074 on 31-Mar-2020	GRANTED
KP002.B/AU3	2020201184 (Australia)	19-Feb-2020	DIV on KP002.B/AU2		PENDING
KP002.B/CA	2,871,745 (Canada) [Pub'd as CA2871745 on 07- Nov-2013]	3-May-2013	Nat'l Stage of KP002.B/WO		PENDING (Published)

PATENT FAMILY: KP003

TITLE(S) NANOCRYSTALS, COMPOSITION AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS

KP003.B/WO	KP003.B/US8	KP003.B/US7	KP003.B/US6	KP003.B/US5	KP003.B/US4	KP003.B/US3	KP003.B/US2	KP003.B/US	KP003.A/USPR	US cases assigned to JHU OUR REF. NO
PCT/US2013/039467 (PCT)	16/923,980 (United States)	15/976,736 (United States) [Pub'd as US2018/0256508 on 13-Sep-2018]	15/616,799 (United States) [Pub'd as US2017/0266120 on 21-Sep-2017]	15/354,704 (United States) [Pub'd as US2017/0128378 on 11-May-2017]	15/187,552 (United States) [Pub'd as US 2016/0287526 on 6-Oct-2016]	14/731,921 (United States) [Pub'd as US2015/0265542 on 24-Sep-2015]	14/731,972 (United States) [Pub'd as US2015/0265543 on 24-Sep-2015]	13/886,493 (United States) [Pub'd as US2013/0323179 on 05-Dec-2013]	61/642,227 (United States)	US cases assigned to JHU will illicense back to Kala, and ex-US cases co-civiled by Kala and JHU  OUR REF. NO  APPLIN NO & COUNTRY FILING DATE
3-May-2013	08-Jul-2020	10-May-2018	7-Jun-2017	17-Nov-2016	20-Jun-2016	5-Jun-2015	5-Jun-2016	3-May-2013	3-May-2012	es co-owned by Kala and JHU FILING DATE
PCT of KP003,A/USPR	CON of KP003.B/US7	CON of KP003.B/US6	CON of KP003.B/US5	CON of KP003.B/US4	CON of KP003.B/US3	CON of KP003.B/US	CON of KP003.B/US	US ORD Filing of KP003.A/USPR	Provisional 1	FAMILY REL'P
		US10,736,854 on 11-Aug-2020	US 10,058,511 on 28-Aug-2018	US 9,737,491 on 22-Aug-2017	US 9,532,955 on 03-Jan-2017	US 9,393,212 on 19-Jul-2016	US 9,393,213 on 19-Jul-2016	US 9,056,057 on 16-Jun-2015		PATENT NO & ISSUE DATE
EXPIRED/ IN NATIONAL STAGE	PENDING	ISSUED	EXPIRED	STATUS						

<b>КР003.В/JP3</b> 2020-152328 20-Sep-2020 DIV of KP003.В/JP2		KP003.B/JP2         2018-117644         3-May-2013         DIV of KP003.B/JP         JP6816065 o	KP003.B/JP         2015-510480         3-May-2013         Nat'l Stage of KP003.B/WO         JP6360039 o           [Pub'd as JP2015519330 on 09-Jul-2015]         [Pub'd as JP2015519330 on 09-Jul-2015]         Nat'l Stage of KP003.B/WO         JP6360039 o	KP003.B/HK-EP       15108780.0       3-May-2013       HK Registration of KP003.B/EP         (Hong Kong)       [Pub'd as HK1208162 on 26-Feb-2016]       HK Registration of KP003.B/EP	KP003.B/EP       13724670.8       3-May-2013       Nat'l Stage of KP003.B/WO         (European Patent Office)         [ Pub'd as EP2844295 on 11-       Mar-2015]	KP003.B/CA         2,871,778         3-May-2013         Nat'l Stage of KP003.B/WO           (Canada)         [Pub'd as CA2871778 on 07-Nov-2013]         Nov-2013]	KP003.B/AU3       2020/203213       18-Apr-2020       DIV of KP003.B/AU2         (Australia)       (Australia)	KP003.B/AU2       2018/201772       13-Mar-2018       DIV of K003.B/AU       AU20182017         (Australia)       [Pub'd as AU2018201772 on 05-Apr-2018]       [Pub'd as AU2018201772 on 05-Apr-2018]       [Pub'd as AU2018201772 on 05-Apr-2018]	3-May-2013 Nat'l Stage of KP003.B/WO 130 on	(Pub'd as WO2013/166385 on 07-Nov-2013)
Nat'l Stage of KP003.B/WO KR-2140989 on 04-Aug-2020		JP6816065 on 20-Jan-2021	WO JP6360039 on 29-Jun-2018	33.B/EP	WO	WO		AU2018201772 on 04-Jun-2020	WO AU2013256130 on 5-Apr-2018	
	PENDING	GRANTED	GRANTED	PENDING (Published)	PENDING (Published)	PENDING (Published)	PENDING	GRANTED	GRANTED	

PATENT FAMILY: KP004					
TITLE(S) Prov 1= COMPOSIT All Others PARTICLE	TITLE(S). Prov. 1= COMPOSITIONS AND METHODS UTILIZING POLYVINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS All Others, PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS.	EOR OPHTHALMIC AND/OR OTH	HER POLYMERS THAT AID PARTICL ER APPLICATIONS	LE TRANSPORT IN MUCUS	
US cases assigned to JHU w/ a	US cases assigned to JHU w. a license back to K.a.a. and ex-US cases exclusively owned by Kaia	s exclusively owned by Kala			
OUR REF NO	APPLINING & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO & ISSUEDATE	STATUS
KP002.A/USPR	61/642,261 (United States)	3-May-2012	Provisional 1		EXPIRED
KP004.A/USPR	61/642,313 (United States)	3-May-2012	Provisional 2		EXPIRED
KP004.B/USPR	61/738,949 (United States)	18-Dec-2012	Provisional 3		EXPIRED
KP004.C/USPR	61/784,701 (United States)	14-Mar-2013	Provisional 4		EXPIRED
KP004.D/US	13/886,602 (United States) [ Pub'd as US2013/0316006 on 28-Nov-2013]	3-May-2013	US ORD of Provisionals 1-4		ABANDONED
KP004.D/US2	13/886,658 (United States) [ Pub'd as US2013/0316001 on 28-Nov-2013]	3-May-2013	Non-Provisional of Prov. 1-4		ABANDONED
KP004.D/US3	15/992,494 (United States) [Pub'd as US2018/0271782 on 27-Sep-2018]	30-May-2018	CON of KP004.D/US		ABANDONED

KP003.B/KR2

10-2020-7022063 (South Korea)

3-May-2013

DIV of KP003.B/KR

PENDING

KP004.D/US4	16/945,398 (United States)	31-Jul-2020	CON of KP004.D/US3		PENDING
KP004.D/WO	PCT/US2013/039540 (PCT Int'l) [Pub'd as WO2013/166436 on 7-Nov-2013]	3-May-2013	PCT of Provisionals 1-4		EXPIRED/ IN NATIONAL STAGE
KP004.D/AU	2013/256092 (Australia) [Pub'd as AU2013256092 on 30-Oct-2014]	3-May-2013	Nat'l Stage of KP004.D/WO	AU2013256092 on 08-Mar-2018	GRANTED
KP004.D/AU2	2018-201215 (Australia)	20-Feb-2018	DIV of KP004.D/AU	AU2018201215 on 28-May- 2020	GRANTED
KP004.D/AU3	2020/023052 (Australia)	08-May-2020	DIV of KP004.D/AU2		PENDING
KP004.D/BR	BR112014027296 (Brazil) [Pub'd as BR112014027296 on 18-Jul-2017]	3-May-2013	Nat'l Stage of KP004.DWO		PENDING (Published)
KP004.D/CA	2,871,748 (Canada) [Pub'd as CA2871748 on 07- Nov-2013]	3-May-2013	Nat'l Stage of KP004.D/WO		PENDING (Published)
KP004.D/CL	2014-2956 (Chile) [Pub'd as CL2014002956 on 02-Oct-2015]	3-May-2013	Nat'l Stage of KP004.D/WO	CL59.839 on 11-Jun-2020	GRANTED
KP004.D/CL2	3433-2019 (Chile)	3-May-2013	DIV of KP004.D/CL		PENDING
KP004.D/CL3	3432-2019 (Chile)	3-May-2013	DIV of KP004.D/CL		PENDING
KP004.D/CN	201380035493.6 (China) [Pub'd as CN104661647 on 27- May-2015]	3-May-2013	Nat'l Stage of KP004.DWO		ABANDONED

KP004.D/HK-CN4	KP004.D/HK-CN3	KP004.D/HK-CN2	KP004.D/HK-EP	KP004.D/HK-CN	KP004.D/EP2	KP004.D/EP	KP004.D/CN5	KP004.D/CN4	KP004.D/CN3	KP004.D/CN2
42021027920.4 (Hong Kong)	2021027919.6 (Hong Kong)	(Hong Kong) 42021028083.0 (Hong Kong)	15108779.3 (Hong Kong) [Pub'd as HK 1208161 on 26- Feb-2016]	15109260.7 (Hong Kong) [Pub'd as HK120838 on 04- Mar-2016]	(European Patent Office)	13723629.5 (European Patent Office) [Pub'd as EP2844223 on 11- Mar-2015]	202010551342 (China) [Pub'd as CN111700880 on 25-Sep-2020]	202010551329 (China) [Pub'd as CN111700879 on 25-Sep-2020]	202010551316 (China) [Pub'd as CN111700878 on 25-Sep-2020]	202010551315 (China) [Pub'd as CN111714472 on 29-Sep-2020]
3/24/2021	3/24/2021	26-Mar-2021	9-Sep-2015	21-Sep-2015		3-May-2013	3-May-2013	3-May-2013	3-May-2013	3-May-2013
HK Registration of KP004.D/CN3	HK Registration of KP004.D/CN3	HK Registration of KP004.D/CN2	HK Registration of KP004.D/EP	HK Registration of KP004.D/CN	DIV of KP004.D/EP	Nat'l Stage of KP004.D/WO	DIV of KP004.D/CN	DIV of KP004.D/CN	DIV of KP004.D/CN	DIV of KP004.D/CN
PENDING	PENDING	PENDING	PENDING (Published)	ABANDONED	In Progress	PENDING (Published)	PENDING	PENDING	PENDING	PENDING

KP004.D/NZ2       728721       31-Jan-2017       DIV of KP004.D/NZ         (New Zealand)       [Pub'd as NZ728721 on 25-May-2018]		KP004.D/NZ       700875       3-May-2013       Nat'l Stage of KP004.D/N         (New Zealand)       [Pub'd as NZ700875 on 31-         Mar-20171       Apr-20171	KP004.D/MX2         Mx/a/2020/007227         3-May-2013         DIV of KP004.D/MX           (Mexico)         (Mexico)	KP004.D/MX         MX/a/2014/013315         3-May-2013         Nat'l Stage of KP004.D/N           (Mexico)         [Pub'd as MX2014013315 on 10-Sep-2015]         10-Sep-2015]	KP004.D/KR2       10-2021-7002733       3-May-2013       DIV of KP004.D/KR         (South Korea)       (South Korea)	KP004.D/KR       10-2014-7033577       3-May-2013       Nat'l Stage of KP004.D/N         (South Korea)       [Pub'd as KR2015-0006869 on 19-Jan-2015]	KP004.D/JP3         2020-193338         3-May-2013         DIV of KP004.D/JP2           (Japan)         (Japan)	KP004.D/JP2         2019-182856         3-May-2013         DIV of KP004.D/JP           (Japan)         (Japan)	3-May-2013 331 on	KP004.D/HK-CN5         42021027921.2         3/24/2021         HK Registration of KP004.D/CN3
Nat'l Stage of KP004.D/WO DIV of KP004.D/MX  Nat'l Stage of KP004.D/WO DIV of KP004.D/NZ	Nat'l Stage of KP004.D/WO  DIV of KP004.D/MX  Nat'l Stage of KP004.D/WO	Nat'l Stage of KP004.D/WO DIV of KP004.D/MX	Nat'l Stage of KP004.D/WO		DIV of KP004.D/KR	Nat'l Stage of KP004.D/WO	DIV of KP004.D/JP2	DIV of KP004.D/JP	Nat'l Stage of KP004.D/WO	HK Registration of KP004.D/CN3
NZ700875 on 07/04/2017 NZ728721 on 08/28/2018	NZ700875 on 07/04/2017								JP6720443 on 22-Jun-2020	
GRANIED	GRANIED	) ]	PENDING	PENDING (Allowed)	PENDING	ABANDONED	PENDING	PENDING	GRANTED	PENDING

27-Apr-2018 DIV of KP004.DIVIZ2 NZ742005 on 30-Jul-2019 3 - May-2013 Nat! Stage of KP004.DIVIS2 US 9,827,191 on 28-Nov-2017 25539 3 - Nov-2017 CON of KP004.E/US2 US 10,688,045 on 23-Jun-2020 064641 11-May-2018 CON of KP004.E/US2 US 10,646,436 on 12-May-2020 280290 29-May-2020 DIV of KP004.E/US2 US 10,646,436 on 12-May-2020 1286497 11-May-2018 CON of KP004.E/US2 US 10,646,437 on 12-May-2020 1256497 08-Jun-2020 CON of KP004.E/US5 US 10,864,219 on 15-Dec-2020 1125758 08-Jun-2020 CON of KP004.E/US5 US 10,867,086 on 08-Dec-2020	KP004.D/NZ4 KP004.D/NZ5	741873 (New Zealand) 742004	23-Apr-2018 27-Apr-2018	DIV of KP004.D/NZ2  DIV of KP004.D/NZ2	NZ741873 on 30-Jul-2019 NZ742004 on 30-Jul-2019	GRANTED GRANTED
(New Zeeland)  (New Z	KP004.D/NZ5	742004 (New Zealand)	27-Apr-2018	DIV of KP004.D/NZ2	NZ742004 on 30-Jul-2019	GRANTED
1401006565   3.May-2013   Nat'l Stage of KP004.D/WO     1401006565   3.May-2013   Nat'l Stage of KP004.D/WO     14070.506   2.Nov-2013   CIP of KP004.D/US2   US 9,827,191 on 28.Nov-2017     14070.506   2.Nov-2013   CIP of KP004.D/US2   US 10,688,045 on 28.Nov-2017     14070.506   2.Nov-2013   CIP of KP004.D/US2   US 10,688,045 on 28.Nov-2017     14070.506   2.Nov-2017   CON of KP004.E/US2   US 10,688,045 on 28.Nov-2017     14070.506   2.Nov-2017   CON of KP004.E/US2   US 10,688,045 on 28.Nov-2017     14070.506   2.Nov-2017   CON of KP004.E/US2   US 10,688,045 on 28.Nov-2017     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004.E/US2   US 10,646,436 on 12.May-2020     14070.506   2.Nov-2018   CON of KP004	KP004.D/NZ6	742005 (New Zealand)	27-Apr-2018	DIV of KP004.D/NZ2	NZ742005 on 30-Jul-2019	GRANTED
1401006565   3-May-2013   Nat'l Stage of KP004.DWO     Pub'd as TH167678 on 07-     Sep_2017    14070.506   2-Nov-2013   CIP of KP004.DWS2   US 9,827,191 on 28-Nov-2017     Flub'd as US20150126539		(New Zealand)				
Pub das   H16778 on 07.	KP004.D/TH	1401006565	3-May-2013	Nat'l Stage of KP004.D/WO		PENDING (Published)
Sep_2017    Sep_2017    Sep_2017    Sep_2017    Sep_2017    Sep_2017    Sep_2017    Sep_2017    Sep_2015    Sep_2016    Sep_2015    Sep_2016    Sep_		(Thailand) [Pub'd as TH167678 on 07-				
CIN   CAUTURS   CANON-2013   CANON-2014   CANON-2017   CANON-2018		Sep-2017]				5
[Pubrid as US2015/01/25539   9-Nov-2017   CON of KP004.E/US   US10,688,045 on 23-Jun-2020   (United States)   [Pubrid as US20180064641   on 08-Mar-2018    11-May-2018   CON of KP004.E/US2   US10,646,436 on 12-May-2020   (United States)   [Pubrid as US20180064641   on 04-Cct-2018    16/828,371   29-May-2020   United States)   [Pubrid as US201080280490   on 29-May-2020]   (United States)   [Pubrid as US20100788409   on 29-May-2020]   (United States)   [Pubrid as US20180256497   on 13-Sep-2018    16/221,253   (United States)   [Pubrid as US20190725758   on 02-May-2020]   16/896,007   (United States)   [Pubrid as US20190725758   08-Jun-2020   CON of KP004.E/US5   US10,864,219 on 15-Dec-2020   (United States)   [Pubrid as US20190725758   08-Jun-2020   CON of KP004.E/US5   US10,864,219 on 15-Dec-2020   (United States)   [Pubrid as US20190725758   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,867,096 on 08-Dec-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,868,045 on 08-Jun-2020   [Pubrid as US 202000297624   08-Jun-2020   CON of KP004.E/US5   US10,868,045 on 12-May-2020	N7004.E/00	(United States)	Z-NOV-ZU 13	CIT OF NEOU4.D/USZ	05 9,827,191 Off 28-NOV-2017	וטטטבט
on 1-May-2015  (Linited States) [Pub'd as US20180064641  on 08-Mar-2018]  (Linited States) [Pub'd as US20180064641  on 04-Cet-2018]  (Linited States) [Pub'd as US20180280290  on 4-Cet-2018]  (Linited States) [Pub'd as US2018028049]  on 28-May-2020]  (Linited States) [Pub'd as US2018028049]  on 29-May-2020]  (Linited States) [Pub'd as US2018028049]  on 29-May-2020]  (Linited States) [Pub'd as US2018028049]  on 13-Sep-2018]  (Linited States) [Pub'd as US2018028049]  on 13-Sep-2018  (Linited States) [Pub'd as US2018028049]  on 14-Sep-2020]  (Linited States) [Pub'd as US2018028049]  on 15-Sep-2018  (Linited States) [Pub'd as US2018028049]  on 16-Zet-2058  (Linited States) [Pub'd as US2018028049]  on 16-Zet-2058  (Linited States) [Pub'd as US2018028049]  on 16-Zet-2058  (Linited States) [Pub'd as US2018028049]  on 16-Zet-2050  (Linited States) [Pub'd as US2018028049]  on 16-Zet-2050  (Linited States) [Pub'd as US2018028049]  (Linited States) [Pu		[Pub'd as US2015/0125539				
CON of KP004_E/US2		on /-May-2015j				
Pub'd as US20180064641	RP004.E/USZ	(United States)	9-NOV-ZUT/	CON OF KP004.E/US	US 10,688,045 on 23-Jun-2020	ISSUED
15/977,911		[Pub'd as US2018/0064641 on 08-Mar-2018]				
(United States) [Pub'd as US20180/280290 on 04-Oct-2018] 29-May-2020 DIV of KP004.E/US2 US10,940, 108 on 09-Mar-2021 (United States) [Pub'd as US 2020/0289409 on 29-May-2020] 15/977,940 (United States) [Pub'd as US20180/256497 on 13-Sep-2018] (United States) [Pub'd as US20180/25758 on 02-May-2019] 16/896,007 (United States) [Pub'd as US20190/125758 on 02-May-2019] 08-Jun-2020 CON of KP004.E/US5 US10,844,219 on 15-Dec-2020 US10,844,219 on 05-Dec-2020 US10,845,29 on 08-Jun-2020 US10,857,096 on 08-Dec-2020 US10,857,096 on 08-Dec-2020	KP004.E/US3	15/977,911	11-May-2018	CON of KP004.E/US2	US10,646,436 on 12-May-2020	ISSUED
[Pub'd as: US201802800 on 04-Oct;2018]  on 04-Oct;2018]  16/888,371  (United States) [Pub'd as: US20200289409 on 29-May-2020]  [Pub'd as: US20200289409 on 29-May-2020]  (United States) [Pub'd as: US20180256497 on 13-Sep-2018]  (United States) [Pub'd as: US20180256497 on 13-Sep-2018]  (United States) [Pub'd as: US2019/0125758 on 02-May-2019]  16/896,007  (United States) [Pub'd as: US2019/025758 on 02-May-2019]  16/896,007  (United States) [Pub'd as: US2019/0297624 on 24-Sep-2020]		(United States)				
16/888,371   29-May-2020   DIV of KP004,E/US2   US10,940,108 on 09-Mar-2021		[Pub'd as US2018/0280290 on 04-Oct-2018]				
(United States) [Pub'd as US 2020/0289409] on 29-May-2020] (United States) [Pub'd as US2018/0256497] on 13-Sep-2018] (United States) [Pub'd as US2018/0256497] on 13-Sep-2018] (United States) [Pub'd as US2019/0125758] on 02-May-2019] (United States) [Pub'd as US2019/0297624] on 24-Sep-2020] [Pub'd as US 2020/0297624] On 24-Sep-2020]	KP004.E/US4	16/888,371	29-May-2020	DIV of KP004.E/US2	US10,940,108 on 09-Mar-2021	ISSUED
on 29-May-2020]  on 29-May-2020]  (United States) [Pub'd as US2018/0256497 on 13-Sep-2018]  (United States) [Pub'd as US2018/0256497 on 13-Sep-2018]  (United States) [Pub'd as US2019/0125758 on 02-May-2019]  16/896,007 (United States) [Pub'd as US 2020/0297624 on 24-Sep-2020]  (United States) [Pub'd as US 2020/0297624 on 24-Sep-2020]		(United States) [Pub'd as US 2020/0289409]				
(United States) [Pub'd as US2018/0256497 on 13-Sep-2018] (United States) [Pub'd as US2018/0256497 on 13-Sep-2018] (United States) [Pub'd as US2019/0125758 on 02-May-2019] (United States) [Pub'd as US2019/0125758 on 02-May-2019] (United States) [Pub'd as US 2020/0297624 on 24-Sep-2020] (United States)		on 29-May-2020]				
[Pub'd as US2018/0256497] on 13-Sep-2018] 16/221,253 (United States) [Pub'd as US2019/0125758 on 02-May-2019] 16/896,007 (United States) [Pub'd as US 2020/0297624 on 24-Sep-2020]  CON of KP004, E/US5 US 10,864,219 on 15-Dec-2020	KP004.E/US5	15/977,940	11-May-2018	CON of KP004.E/US2	US10,646,437 on 12-May2020	ISSUED
on 13-Sep-2018]  16/221,253 (United States) [Pub'd as US2019/0125758 on 02-May-2019]  16/896,007 (United States) [Pub'd as US2020/0297624 on 24-Sep-2020]  On 03-May-2019]  On 04-Sep-2020]  On 04-Sep-2020]  On 05-May-2019  On 08-Jun-2020  CON of KP004.E/US5 US10,864,219 on 15-Dec-2020 US10,864,219 on 15-Dec-2020 US10,864,219 on 15-Dec-2020 US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020  US10,864,219 on 15-Dec-2020		(United States) [Pub'd as US2018/0256497				
[Pub'd as US201/25758] [Pub'd as US201/25758] [Pub'd as US2019/0125758] [Pub'd as US2019/0125758] [Pub'd as US2019/0125758] [Pub'd as US 2020/0297624]		on 13-Sep-2018]				
(United States) [Pub'd as US2019/0125758 on 02-May-2019] 16/896,007 08-Jun-2020 CON of KP004.E/US5 US10,857,096 on 08-Dec-2020 [Pub'd as US 2020/0297624 on 24-Sep-2020]	KP004.E/US6	16/221,253	14-Dec-2018	CON of KP004.E/US5	US10,864,219 on 15-Dec-2020	ISSUED
[Pub d as US2019/0125/38 on 02-May-2019] 0n 02-May-2019]		(United States)				
16/896,007 08-Jun-2020 CON of KP004.E/US5 US10,857,096 on 08-Dec-2020 (United States) [Pub'd as US 2020/0297624 on 24-Sep-2020]		[Pub'd as US2019/0125758 on 02-May-2019]				
(United States) [Pub'd as US 2020/0297624 on 24-Sep-2020]	KP004.E/US7	16/896,007	08-Jun-2020	CON of KP004.E/US5	US10,857,096 on 08-Dec-2020	ISSUED
on 24-Sep-2020]		(United States) [Pub'd as US 2020/0297624				
		on 24-Sep-2020]				

KP004.E/US8	16/988,459 (United States) [Pub'd as US20200/368154	07-Aug-2020	CON of KP004.E/US4	US10,945,948 on 16-Mar-2021	ISSUED
	on 26-Nov-2020]				
KP004.E/US9	16/988,470 (United States) Pub'd as US2020/0368155 on 26-Nov-20201	07-Aug-2020	CON of KP004.E/US4	US 10,993,908on 04-May-2021	ISSUED
KP004.E/US10	17/170,701 (United States)	08-Feb-2021	CON of KP004.E/US9		PENDING
KP004.E/US11	17/207,442 (United States)	19-Mar-2021	CON of KP004.E/US9		PENDING
KBOOA E/I ISA3	47/207 467	40 Mar 2024	CON of KDOON EN ISO		סווסווס
KP004.E/US13	1//207,467 (United States)	19-Mar-2021	CON of KP004.E/US9		PENDING
KP004.E/WO	PCT/US2014/063373 (PCT Int'I) [Pub'd as WO2015/066444 on 07-May-2015]	31-Oct-2014	PCT of KP004.E/US		EXPIRED/ IN NATL STAGE
KP004.E/AU	2014/342097 (Australia) [Pub'd as AU2014342097 on 12-May-2016]	31-Oct-2014	Nat'l Stage of KP004.E/WO	AU2014342097 on 21-Dec- 2017	GRANTED
KP004.E/CA	2,928,969 (Canada) [Pub'd as CA2928969 on 07- May-2015]	31-Oct-2014	Nat'l Stage of KP004.E/WO		PENDING (Published)
KP004.E/CN	201480071942.7 (China) [Pub'd as CN105916509 on 31-Aug-2016]	31-Oct-2014	Nat'l Stage of KP004.E/WO	CN105916509 on 17-Jun-2020	GRANTED
KP004.E/CN2	202010578302.2 (China) [Pub'd as CN111743878 on 09-Oct-2020]	31-Oct-2014	DIV of KP004.E/CN		PENDING
KP004.E/CN3	202010578480 (China) [Pub'd as CN111743879 on 09-Oct-2020]	31-Oct-2014	DIV of KP004.E/CN		PENDING
			-		

KP004.E/EP	14858272.9	31-Oct-2014	Nat'l Stage of KP004.E/WO		PENDING (Published)
	(European Patent Office) [Pub'd as EP3062796 on 07- Sep-2016]				
KP004.E/EP2	(European Patent Office)		DIV of KP004.E/EP		In Progress
KP004.E/HK-CN	17100500.4 (Hong Kong) [Pub'd as HK 1226949 on 13-	16-Jan-2017	HK Registration of KP004.E/CN		PENDING (Published)
KP004.E/HK-EP	17100086.6	4-Jan-2017	HK Registration of KP004.E/EP		PENDING (Published)
	(Hong Kong) [Pub'd as HK1226333 on 29- Sep-2017]		,		
KP004.E/HK-CN2	42021028763.7 (Hong Kong)		HK Registration of KP004.E/CN2		PENDING
KP004.E/HK-CN3	42021028764.5 (Hong Kong)		HK Registration of KP004, E/CN3		PENDING
KP004.E/IN	201617014248 (India)	31-Oct-2014	Nat'l Stage of KP004.E/WO	IN359759 on 26-Feb-2021	Granted
	[Pub'd as IN36/2016 on 31- Aug-2016]				
KP004.E/IN2	202018056794 (India)	31-Oct-2014	DIV of KP004.E/IN		PENDING
KP004.E/JP	2016-552253 (Japan) [Pub'd as JP2016535777 on 11-Nov-2016]	31-Oct-2014	Nat'l Stage of KP004,E/WO	JP6751669 on 19-Aug-2020	GRANTED
KP004.E/JP2	2019-219516 (Japan)	31-Oct-2014	DIV of KP004.E/JP2		PENDING
KP004.E/MX	MX/a/2016/005710 (Mexico) [Pub'd as MX2016005710 on 08-Feb-2017]	31-Oct-2014	Nat'l Stage of KP004.EWO		PENDING (Allowed)

PATENT FAMILY: KP005 TITLE(S) THERAPEUTIC COM Assignee: Kala	PATENT FAMILY. KP005 THEE(S): THERAPEUTIC COMPOUNDS AND USES THEREOF Assignee: Kala				
OUR REF NO	APPLIN NO & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP005.A/USPR	61/765,487 (United States)	15-Feb-2013	Provisional 1		EXPIRED
KP005,A/WO	PCT/US2014/016763 (PCT Int'I) [Pub'd as WO2014/127335 on 21-Aug-2014]	18-Feb-2014	PCT of KP005.A/USPR		EXPIRED/ IN NATIONAL STAGE
KP005.A/US	14/768,038 (United States) [Pub'd as US2016/0002254 on 07-Jan-2016]	14-Aug-2015 (371 Date)	Nat'l Stage of KP005.A/WO	US 9,695,184 on 4-Jul-2017	ISSUED
KP005.B/USPR	61/898,778 (United States)	1-Nov-2013	Provisional 2		EXPIRED
KP005.C/US	14/181,095 (United States) [Pub'd as US2014/0235634 on 21-Aug-2014]	14-Feb-2014	US ORD of KP005.A & .B/USPR	US 9,353,122 on 31-May-2016	ISSUED
KP005.C/US2	15/139,099 (United States) [Pub'd as US2016/0235761 on 18-Aug-2016]	26-Apr-2016	CON of KP005.C/US	US 9,827,248 on 28-Nov-2017	ISSUED
KP005.C/US3	15/139,107 (United States) [Pub'd as US2016/0237093 on 18-Aug-2016]	26-Apr-2016	DIV of KP005.C/US	US 9,877,970 on 30-Jan-2018	ISSUED

KP004.E/NZ
719182 (New Zealand)
31-Oct-2014
Nat'l Stage of KP004.E/WO
ABANDONED

KP005.C/JP	KP005.C/HK-EP	KP005.C/EP	KP005.C/CA	KP005.C/AU2	KP005.C/AU	KP005.C/WO	KP005.C/US6	KP005.C/US5	KP005.C/US4
2015-558148 (Japan) [Pub'd as JP2016513108 on 12-May-2016]	16105107.1 (Hong Kong) [Pub'd as HK1217092 on 23- Dec-2016]	14751929.2 (European Patent Office) [Pub'd as EP2956138 on 23- Dec-2015]	2,900,652 (Canada) [Pub'd as CA2900652 on 21- Aug-2014]	2018-229493 (Australia)	2014/216,178 (Australia) [Pub'd as AU2014216178 on 03-Sep-2015]	PCT/US2014/016439 (PCT Int'I) [Pub'd as WO2014/127214 on 21-Aug-2014]	17/180,388 (United States)	16/522,550 (United States) [Pub'd as US2020/0054644 on 20-Feb-2020]	15/868,894 (United States) [Pub'd as US2018/0133225 on 17-May-2018]
14-Feb-2014	20-Feb-2014	14-Feb-2014	14-Feb-2014	14-Feb-2014	14-Feb-2014	14-Feb-2014	19-Feb-2021	25-Jul-2019	11-Jan-2018
Nat'l Stage of KP005.C/WO	HK Registration of KP005.C/EP	Nat'l Stage of KP005.C/WO	Nat'l Stage of KP005.C/WO	DIV of KP005.C/AU	Nat'l Stage of KP005.C/WO	PCT of KP005.A & .B/USPR	CON of KP005.C/US5	CON of KP005.C/US4	CON of KP005.C/US3
JP6669499 on 18-Mar-2020			CA2900652 on 05-Apr-2021		AU2014216178 on 11-Oct-2018			US10,966,987 on 06-Apri-2021	US10,398,703 on 03-Sep-2019
GRANTED	PENDING (Published)	PENDING (Published)	GRANTED	To Be Abandoned	GRANTED	EXPIRED/ IN NATIONAL STAGE	PENDING	ISSUED	ISSUED

PATENT FAMILY: KP006 TITLE(S) THERAPEUTIC CON Assignme Kaia OUR REF. NO	PATENT FAMILY: KP006  TITLE(S) THERAPEUTIC COMPOUNDS AND USES THEREOF ASSignee. Kala  OUR REF. NO. APPL'N NO. & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE
KP006.A/USPR	61/767,087 (United States)	20-Feb-2013	Provisional 1	
KP006.B/USPR	61/898,741 (United States)	1-Nov-2013	Provisional 2	
KP006.C/US	14/184,886 (United States) [Pub'd as US2014/0235657 on 21-Aug-2014]	20-Feb-2014	US ORD of KP006.A & .B/USPR	US 9,353,123 on 31-May-2016
KP006.C/US2	15/139,121 (United States) [Pub'd as US2016/0235753 on 18-Aug-2016]	26-Apr-2016	CON of KP006.C/US	US 9,833,453 on 5-Dec-2017
KP006.C/US3	15/139, 135 (United States) [Pub'd as US2016/0237094 on 18-Aug-2016]	26-Apr-2016	DIV of KP006.C/US	US 9,861,634 on 9-Jan-2018
KP006,C/US4	15/842,695 (United States) [Pub'd as US2018/0104246 on 19-Apr-2018]	14-Dec-2017	CON of KP006.C/US3	US10,285,991 on 14-May-2019
KP006. C/US5	16/361,732 (United States) [Pub'd as US2019/0216812 on 18-Jul-2019]	22-Mar-2019	Con of KP006.C/US4	US10,758,539 on 01-Sep-2020
KP006,C/US6	16/915,508 (United States) [Pub'd as US2020/0323854 on 29-Jun-2020]	29-Jun-2020	CON of KP006.C/US5	
KP006.CWO	PCT/US2014/017270 (PCT Int'l)	20-Feb-2014	PCT of KP006.A & .B/USPR	

KP006.C/EP-ES	KP006.C/EP-DE	KP006.C/EP-CH	KP006.C/EP	KP006.C/CN2	KP006.C/CN	KP006.C/CA	KP006.C/BR	KP006.C/AU2	KP006.C/AU	
(Spain)	(Germany)	(Switzerland)	14754329.2 (European Patent Office) [Pub'd as EP2958895 on 30-Dec-2015]	201710946816.7 (China) [Pub'd as CN107915751 on 17-Apr-2018]	2014800212484.8 (China) [Pub'd as CN105189462 on 23-Dec-2015]	2,900,680 (Canada) [Pub'd as CA2900680 on 28- Aug-2014]	2015-1120139 (Brazil) [Pub'd as BR112015020139 on 18-Jul-2017]	2018/202,312 (Australia) [Pub'd as AU2018202312 on 26-Apr-2018]	2014/219,024 (Australia) [Pub'd as AU2014219024 on 05-Apr-2018]	[Pub'd as WO2014/130612 on 28-Aug-2014]
			20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	
Valid. of KP006, C/EP	Valid. of KP006.C/EP	Valid. of KP006.C/EP	Nat'l Stage of KP006.C/WO	DIV of KP006.C/CN	Nat'l Stage of KP006.C/WO	Nat'l Stage of KP006.C/WO	Nat'l Stage of KP006.C/WO	DIV of KP006.C/AU	Nat'l Stage of KP006.C/WO	
			EP2958895 on 19-Aug-2020		CN105189462 on 10-Nov-2017			AU2018202312 on 13-Feb-2020	AU2014219024 on 19-Jul-2018	
			GRANTED	PENDING (Published)	GRANTED	PENDING (Allowed)	PENDING (Published)	GRANTED	GRANTED	

<b>KP006.C/JP2</b> 2018-229512 20-Feb-2014 (Japan)	<b>KP006. C/JP</b> 2015-558936 20-Feb-2014 (Japan) [Pub'd as JP2016510000 on 04-Apr-2016]	KP006.C/IN  2354/MUMNP/2015  (India)  [Pub'd as IN22/2016 on 27-  May-2016]  20-Feb-2014	KP006, C/HK-EP       16105120.4       20-Feb-2014         (Hong Kong)       [Pub'd as HK1217191 on 30-Dec-2016]	<b>KP006.C/HK-CN2</b> 18113257.1  (Hong Kong)  [Pub'd as HK1254296 on  19-Jul-2019]	KP006.C/EP2 20191413.2 20-Feb-2014  (European Patent Office) [Pub'd as EP3763710 on 31- Jan-2021)	KP006.C/EP-NE (Netherlands)	KP006.C/EP-IT (Italy)	KP006.C/EP-IE (Ireland)	KP006.C/EP-GB (Great Britain)	
-2014 DIV of KP006.C/JP	-2014 Nat'l Stage of KP006.C/WO	-2014 Nat'l Stage of KP006.C/WO	-2014 HK Registration of KP006, C/WO	-2014 HK Registration of KP006.C/CN2	-2014 DIV of KP006.C/EP	Valid. of KP006.C/EP	Valid. of KP006.C/EP	Valid. of KP006. C/EP	Valid. of KP006.C/EP	
PENDING (Allowed)	ABANDONED	PENDING (Published)	PENDING (Published)	PENDING (Published)	PENDING (Published)					

		OUR REF NO		mooy/oc./\ara				=	ı			PATENT FAMILY KPM7	
		S		ě	2			ř	i.			7	
		70		ž				Щ	1			3	
		Ψ.		ă				Y					
			×	2	₹			3				5	
		ð	×	ž	) }			7	1			Ξ	
			×					Ĉ		×		░	
								n	ì				
			×					Ž			×	×	
								ž	×			Ų	
			×					Ċ	۱			Ħ	
								7			×		
		<b>***</b>						ζ					
								2			×		
								≤				*	
		2	×	8				ö	ì	×	×		
		Ð	×					Ž					
		×						É	ì	×	×		
			×					¢					
		Ø		×				й	1	×	×		
		ga.						V					
		APPL'N NO. & COUNTRY		<b>#</b>								ø	<b>*</b>
		z						ឡ	ľ		*	ø	
								Û	ľ			8	
		***						÷	í			ø	
									8			#	
		₩		0					<b>#</b>			×	
									8			<b>#</b>	
				8		ø			<b>#</b>			<b>#</b>	<b>#</b>
						8			8	<b>*</b>		<b>#</b>	
				0		ø			<b>#</b>			<b>#</b>	
		***							*				
			×			×			×				
		룱							8				
				8					*			*	
		FILING DATE							8				
		m							*			*	
		▓							8				
			×	8					*			*	
								×	×		×		
									*			▓	
	***	*	×	▓					×		×		
		W	×						8				
		FAMILY REL'P		*					*				
		₩.	×						8				
			×						*			*	
		ũ							8				
		#							*			*	
									8			8	
				0					*			ø	
									8			<b>#</b>	8
				0		8			8			ø	*
									*		*	ø	
									8	*		<b>#</b>	
									<b>#</b>			ø	
									8				
						ø			<b>*</b>		*	ø	ø
		翻				8			8			8	
		酃		8					8			<b>#</b>	<b>#</b>
									8		×		
		Ø							*	×			
		Ço						×		×	×		
		(n							8			<b>*</b>	
		& ISSUE DATE							8			8	
		嫐							8			<b>#</b>	<b>#</b>
		8							8			8	
									8			<b>#</b>	
				0		8			<b>#</b>			<b>#</b>	
						*			8	<b>*</b>		<b>#</b>	
		Ø		0		8			8			<b>#</b>	
		3				*			8			<b>#</b>	
									*			8	
		Ø				8			8			8	
						ø			*	<b>*</b>		8	
				0		8			<b>#</b>			×	
						ø			8	<b>*</b>		8	
						8			8			8	
						8			8			*	
						8			8			8	
						8			8	<b>*</b>		<b>#</b>	
4444		errich	4	11	10	"	ari.						
		<b>##</b>		▒		×		▓	8			▒	

KP006.C/NZ3DIV	KP006.C/NZ3	KP006.C/NZ2DIV	KP006.C/NZ2	KP006.C/NZDIV	KP006.C/NZ	KP006.C/MX	KP006.C/KR
768859 (New Zealand)	750897 (New Zealand)	768858 (New Zealand)	750895 (New Zealand)	768857 (New Zealand)	711050 (New Zealand)	MX/a/2015/010829 Mexico [Pub'd as MX2015010829 on 03-Dec-2015]	10-2015-7025432 (South Korea) [Pub'd as KR20150119361 on 23-Oct-2015]
20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014	20-Feb-2014
DIV of KP006.C/NZ3	DIV of KP006.C/NZ	DIV of KP006.C/NZ2	DIV of KP006.C/NZ	DIV of KP006.C/NZ	Nat'l Stage of KP006.C/WO	Nat'l Stage of KP006. C/WO	Nat'l Stage of KP006.C/WO
						MX368903 on 20-Feb-2020	
PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	GRANTED	PENDING (Allowed)

Provisional  PCT of KP007.A/USPR  PCT of KP007.B/WO  Nat'l Stage of KP007.B/WO  Nat'l Stage of KP007.B/WO  Nat'l Stage of KP007.B/WO  Validation of KP007.B/WO  Validation of KP007.B/EP  Validation of KP007.B/EP		AU2014227737 on 30-Aug- 2018 EP2968274 on 16-Oct-2019
--	--	---

KP008.B/USPR	KP008.A/USPR	OUR REF. NO.	Assignee Kaia	PATENT FAMILY KP008
61/898,719 (United States)	61/829,117 (United States)	APPLINING & COUNTRY	to the trace of the trace	ne augulete fundeos
1-Nov-2013	30-May-2013	FILING DATE		
Provisional 2	Provisional 1	FAMILY REL'P		
		PATENT NO. & ISSUE DATE STATUS		
EXPIRED	EXPIRED	STATUS		

KP007 R/IN	2654/MHMNP/2015	15-Mar-2014	Nat'l Stage of KP007 R/M/O		PENDING (Published)
	(India)		C		•
	[Pub'd as IN30/2016 on 22-				
	Jul-2018]				
KP007.B/JP	2016-502851	15-Mar-2014	Nat'l Stage of KP007.B/WO		ABANDONED
	(Japan)				
	[Pub'd as JP2016517435 on				
	16-Jun-2016]				
KP007.B/JP2	2019-023946	15-Mar-2014	Div. of KP007.B/JP	JP6738918 on 22-Jul-2020	GRANTED
	(Japan)				
KP007.B/US	14/777,018	15-Sep-2015	Nat'l Stage of KP007.B/WO	US 9,725,451 on 8-Aug-2017	ISSUED
	(United States)	(371 Date)			
	[Pub'd as US2016/0039823				
	on 11-Feb-2016]				
KP007.B/US2	15/650,667	14-Jul-2017	CON of KP007.B/US	US10,392,388 on 27-Aug-2019	ISSUED
	(United States)				
	[Pub'd as US2017/0349590				
	on 07-Dec-2017]				
KP007.B/US3	16/509,388	11-Jul-2019	CON of KP007.B/US2		PENDING (Allowed)
	(United States)				
	[Pub'd as US2020/0010470				
	on 09-Jan-2020]				

30-May-2014  Nat'l Stage of KP008.C/WO  Validation of KP008.C/EP  Nat'l Stage of KP008.C/WO  25-Nov-2015 (371 Date)  Nat'l Stage of KP008.C/WO  CON of KP008.C/US	KP008.C/WO KP008.C/AU KP008.C/CA	PCT/US2014/040231 (PCT Int'l) [Pub'd as WO2014/197313 on 11-Dec-2014] 2014/275198 (Australia) [Pub'd as AU2014275198 on 10-Dec-2015] 2,913,417	30-May-2014 30-May-2014 30-May-2014	PCT of KP008.A & .B/USPR  Nat'l Stage of KP008.C/WO  Nat'l Stage of KP008.C/WO	AU2014275198 on 30-Jul-2017	EXPIRED/ IN NATIONAL STAGE  GRANTED  GRANTED  PENDING (Published)
14807232.5   30-May-2014   Nat'l Stage of KP008.C/WO   [European Pateint Office)   [Pub'd as EP3003314 on 13-Apr-2016]   Validation of KP008.C/EP   (Germany)   Validation of KP008.C/EP   (Germany)   Validation of KP008.C/EP   (France)   Validation of KP008.C/EP   (Hong Kong)   (France)   Validation of KP008.C/EP   (Hong Kong)   (Japan)   (Jap	KP008.C/CA	2,913,417 (Canada) [Pub'd as CA2913417 on 11- Dec-2014]	30-May-2014	Nat'l Stage of KP008.C/WO		
(Germany) Validation of KP008.C/EP  (France) Validation of KP008.C/EP  (Great Britain) Validation of KP008.C/EP  (Great Britain) Validation of KP008.C/EP  (Hong Kong) [Pub'd as HK1223307 on 28- Jul-2017] 2016-571041 30-May-2014 HK Registration of KP008.C/EP  (Japan) [Pub'd as JP2016520617 on 14-Jul-2016] 14-Jul-2016] 25-Nov-2015 Nat'l Stage of KP008.C/WO  (United States) [Pub'd as US20160/137646 on 19-May-2016] 3-May-2018 CON of KP008.C/US  [Pub'd as US201800251467 on 6.5ap-2018] CON of KP008.C/US	KP008.C/EP	14807232.5 (European Patent Office) [Pub'd as EP3003314 on 13- Apr-2016]	30-May-2014	Nat'l Stage of KP008.C/WO	EP3003314 on 14-May-2019	19
(Great Britain)  (Hong Kong)  [Pub'd as HK 1223307 on 28-  Jul-2017]  2016-517041  (Japan)  [Pub'd as JP2016520617 on 14-Jul-2016]  (Japan)  [Pub'd as JP2016520617 on 14-Jul-2016]  (United States)  [Pub'd as US2016/0137646  on 19-May-2016]  (United States)  [Pub'd as US2018/0251467  on 06-Sep-2018]  (CON of KP008.C/US	KP008.C/EP-DE	(Germany)		Validation of KP008.C/EP		
(Great Britain)  (Hong Kong)  [Pub'd as HK1223307 on 28- Jul-2017]  2016-517041  (Japan)  [Pub'd as JP2016520617 on  14-Jul-2016]  (Juli-2016]  (United States)  [Pub'd as US2016/0137646  (United States)  [Pub'd as US2018/0251467  on 06-Sep-2018]  (CN of KP008.C/WO	KP008.C/EP-FR	(France)		Validation of KP008.C/EP		
C-EP       16111737.7       30-May-2014       HK Registration of KP008.C/EP         (Hong Kong)       [Pub'd as HK1223307 on 28-Jul-2017]       HK Registration of KP008.C/EP         2016-517041       30-May-2014       Nat'l Stage of KP008.C/WO         (Japan)       [Pub'd as JP2016520617 on 14-Jul-2016]       Nat'l Stage of KP008.C/WO         (United States)       (United States)       (371 Date)         [Pub'd as US2016/0137646 on 19-May-2016]       3-May-2018       CON of KP008.C/US         (United States)       [Pub'd as US2018/0251467 on 06-Sep-2018]       CON of KP008.C/US	KP008.C/EP-GB	(Great Britain)		Validation of KP008.C/EP		
2016-517041 30-May-2014 Nat'l Stage of KP008.C/WO (Japan) [Pub'd as JP2016520617 on 14-Jul-2016] 25-Nov-2015 Nat'l Stage of KP008.C/WO (United States) [Pub'd as US2016/0137646 on 19-May-2016] 3-May-2018 (United States) [Pub'd as US2018/0251467 on 06-Sep-2018] CON of KP008.C/US	KP008.C/HK-EP	16111737.7 (Hong Kong) [Pub'd as HK1223307 on 28- Jul-2017]	30-May-2014	HK Registration of KP008.C/EP		
14/894,214   25-Nov-2015   Nat'l Stage of KP008.C/WO (United States)   (371 Date)     (371 Date)     (371 Date)     (371 Date)     (371 Date)     (371 Date)     (371 Date)	KP008.C/JP	2016-517041 (Japan) [Pub'd as JP2016520617 on 14-Jul-2016]	30-May-2014	Nat'l Stage of KP008.C/WO	JP6557654 on 19-Jul-2019	
15/970,740 3-May-2018 CON of KP008.C/US (United States) [Pub'd as US2018/0251467 on 06-Sep-2018]	KP008.C/US	14/894,214 (United States) [Pub'd as US2016/0137646 on 19-May-2016]	25-Nov-2015 (371 Date)	Nat'l Stage of KP008.C/WO	US 9,988,386 on 5-Jun-2018	8
-	KP008.C/US2	15/970,740 (United States) [Pub'd as US2018/0251467 on 06-Sep-2018]	3-May-2018	CON of KP008.C/US	US 10,351,570 on 16-Jul-2019	019

PATENT FAMILY: KP009 TITLE(S): UREA DERIVATIVES AND USES THEREOF	AND USES THEREOF				
Assignee Kala					
OUR REF NO	APPLINIO & COUNTRY	FILING DATE	FAMILY RELP	PATENT NO. & ISSUE DATE	STATUS
KP009.A/USPR	61/833,853 (United States)	11-Jun-2013	Provisional 1		EXPIRED
KP009.B/USPR	61/898,720 (United States)	1-Nov-2013	Provisional 2		EXPIRED
KP009.C/US	14/301,653 (United States) [Pub'd as US 2015/0072986 on 12-Mar-2015]	11-Jun-2014	US ORD of KP009.A & .B/USPR	US 9,212,145 on 15-Dec-2015	ISSUED
KP009.C/US2	14/939,727 (United States) [Pub'd as US 2016/0060264 on 03-Mar-2016]	12-Nov-2015	DIV of KP009.C/US	US 9,580,421 on 28-Feb-2017	ISSUED
KP009.C/US3	15/411,485 (United States) [Pub'd as US2017/0129876 on 11-May-2017]	20-Jan-2017	DIV of KP009.C/US2	US 9,802,922 on 31-Oct-2017	ISSUED

KP008.C/US5	KP008.C/US4	KP008.C/US3
17/165,791 (United States)	16/422,606 (United States) [Pub'd as US2020/0157106 on 21-May-2020]	16/014,937 (United States) [Pub'd as US2019/0023710 on 24-Jan-2019]
02-Feb-2021	24-May-2019	21-Jun-2018
CON of KP008.C/US4	DIV of KP008.C/US2	CON of KP008.C/US2
	US10,954,244 on 23-Mar-2021	US10,544,151 on 28-Jan-2020
PENDING	ISSUED	ISSUED

KP009.C/US5  KP009.C/US6  KP009.C/US7  KP009.C/US8  KP009.C/US8  KP009.C/US9	15/782,696 (United States) [Pub'd as US2018/0037572 on 18-Feb-2018] 15/782,743 (United States) [Pub'd as US2018/037573 on 18-Feb-2018] 16/043,000 (United States) [Pub'd as US2018/0327389 on 15-Nov-2018] 16/043,007 (United States) [Pub'd as US2018/0327390 on 15-Nov-2018] 16/400,672 (United States) [Pub'd as US2019/0284172 on 19-Sep-2019] 16/900,657 (United States) [Pub'd as WS2014/041930 (PCT Intl) [Pub'd as WO2014/201127 on 18-Dec-2014] 2014/278231	12-Oct-2017 12-Oct-2017 23-Jul-2018 26-Jul-2018 26-Jul-2019 11-Jun-2020 11-Jun-2014	CON of KP009.C/US3  CON of KP009.C/US5  CON of KP009.C/US5  CON of KP009.C/US5  CON of KP009.C/US7  CON of KP009.C/US7	US 10,059,692 on 28-Aug-2018 US 10,059,693 on 28-Aug-2018 US 10,316,022 on 11-Jun-2019 US 10,329,280 on 25-Jun-2019 US 10,723,719 on 28-Jul-2020 AU2014278231 on 7-Sep-2017	ISSUED ISSUED ISSUED ISSUED ISSUED ISSUED ISSUED ISSUED
KP009.C/WO	PCT/US2014/041930 (PCT Intl) [Pub'd as WO2014/201127 on 18-Dec-2014]	11-Jun-2014	PCT of KP009,A & KP009,B/USPR		EXPIRED/ IN NATIONAL STAGE
KP009.C/AU	2014/278231 (Australia) [Pub'd as AU2014278231 on 24-Dec-2015]	11-Jun-2014	Nat'l Stage of KP009.C/WO	AU2014278231 on 7-Sep-2017	GRANTED
KP009.C/AU2	2017/219063 (Australia) [Pub'd as AU2017219063 on 14-Sep-2017]	24-Aug-2017	DIV of KP009.C/AU		PENDING (Allowed)
KP009.C/AU3	2020233692 (Australia)	16-Sep-2020	DIV of KP009.C/AU2		PENDING
KP009.C/CA	2,914,815 (Canada) [Pub'd as CA2914815 on 18- Dec-2014]	11-Jun-2014	Nat'l Stage of KP009.CWO		PENDING (Published)

KP011.A/USPR	KP006.B/USPR	OUR REF NO	Assignee: Kala	TITLE(S) (A)(D) CRYSTALLIN	PATENT FAMILY KP011
62/039,200 (United States)	61/898,741 (United States)	APPL N NO. & COUNTRY		TITLE(S) (A)-(D) CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF	
19-Aug-2014	1-Nov-2013	FILING DATE		OUNDS AND USES THEREOF	
Provisional 2	Provisional 1	FAMILYRELP			
		PATENT NO. & ISSUE DATE			
Expired	Expired	STATUS			

KP009.C/EP	14811423.4	11-Jun-2014	Nat'l Stage of KP009.C/WO		PENDING (Allowed)
	(Europe Patent Office) [Pub'd as EP3030239 on 15- Jun-2016]				
KP009.C/EP2		11-Jun-2014	DIV of KP009.C/EP		In Progress
	(Europe)				
KP009.C/HK-EP	16113560.5	28-Nov-2016	HK Registration of KP009.C/EP		PENDING (Published)
	(Hong Kong) [Pub'd as HK 1225376 on 08- Sep-2017]				
KP009.C/JP	2016-519614	11-Jun-2014	Nat'l Stage of KP009.C/WO	JP6469661 on 25-Jan-2019	GRANTED
	(Japan) [Pub'd as JP2016534030 on				
	04-Nov-2016]				
KP009.C/JP2	2019-004872	16-Jan-2019	Div of KP009.C/JP		ABANDONED
	(Japan)				
KP009.C/JP3	(Japan)		Div of KP009.C/JP2		PENDING

KP011.E/AU	KP011.E/WO	KP011.E/US6	KP011.E/US5	KP011.E/US4	KP011.E/US3	KP011.E/US2	KP011.E/US	KP011.D/USPR	KP011.C/USPR	KP011.B/USPR
2014/342042 (Australia)	PCT/US2014/063444 (PCT Int'l) [Pub'd as WO2015/066482 on 05/07/2015]	17/197,702 (United States)	16/184,760 (United States) [Pub'd as US2020-0216459 on 09-Jul-2020]	16/184,760 (United States) [Pub'd as US2019-0077810 on 14-Mar-2019]	15/712,645 (United States) [Pub'd as US2018/000982 on 11-Jan-2018]	14/981,105 (United States) [Pub'd as US2016/0115176 on 28-Apr-2016]	14/530,092 (United States) [Pub'd as US2015/0125535 on 7-May-2015]	62/039,177 (United States)	62/039, 185 (United States)	62/039,192 (United States)
31-Oct-2014	31-Oct-2014	10-Mar-2021	02-Mar-2020	08-Nov-2018	22-Sep-2017	28-Dec-2015	31-Oct-2014	19-Aug-2014	19-Aug-2014	19-Aug-2014
National Stage of KP011.E/WO	PCT of Provisionals 1, 3, & 5	CON of KP011.E/US5	CON of KP011.E/US4	CON of KP011.E/US3	CON of KP011.E/US2	DIV of KP011.E/US	US ORD of Provisionals 1, 3 & 5	Provisional 5	Provisional 4	Provisional 3
AU2014342042 on 30-Nov- 2017			US10,975,090 on 13-Apr-2021	US 10,618,906 on 04-Apr-2020	US 10,160,765 on 25-Dec-2018	US 9,790,232 on 17-Oct-2017	US 9,458,169 on 4-Oct-2016			
GRANTED	EXPIRED/ IN NATIONAL STAGE	PENDING	ISSUED	ISSUED	ISSUED	ISSUED	ISSUED	Expired	Expired	Expired

(Hong Kong) [Pub'd as HK 1228197 on 03- Nov-2017] 201627014017 31-Oct-2014 National Stage of KP011.E/WO (India) [Pub'd as IN19/2017 on 12- May-2017]	(Hong Kong) [Pub'd as HK1228197 on 03-	KP011 F/HK.FD 17102021 0 31.0ct-2014 HK Registration of KD011 FAMO HK1228197 or	KP011.E/EP-GB (Great Britain) EP validation of KP011.E/EP	KP011.E/EP-FR France EP validation of KP011.E/EP	KP011.E/EP-DE (Germany) EP validation of KP011.E/EP	31-Oct-2014 National Stage of KP011.E/WO	KP011.E/CN2       201810252366.6       31-Oct-2014       DIV of KP011.E/CN         (China)       [Pub'd as CN108530458 on 14-Sep-2018]       DIV of KP011.E/CN	KP011.E/CN         201480065624.X         31-Oct-2014         National Stage of KP011.E/WO         CN106061261           [Pub'd as CN106061261 on 26-Oct-2016]         26-Oct-2016]         National Stage of KP011.E/WO         CN106061261	31-Oct-2014	Pub'd as AU2014342042 on 12-May-2016]
70 HK1228197 on 05-Feb-2021		4				D EP3062618 on 05-Fe-2020		CN106061261on 24-Apr-2018	0	
	ABANDONED	GRANTED	GRANTED	GRANTED	GRANTED	GRANTED	ABANDONED	GRANTED	ABANDONED	

PATENT FAMILY: KP012					
TITLE(S): CRYSTALLINE FORM	TITLE(S): CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF	AND USES THEREOF			
Assignee Kala					
OUR REF NO	APPL N NO. & COUNTRY	FILING DATE	FAMILY REL'P	PATENT NO. & ISSUE DATE	STATUS
KP006.B/USPR	61/898,741 (United States)	1-Nov-2013	Provisional		EXPIRED
KP006.C/US	14/184,886 (United States) [Pub'd as US2014/0235657 on 21-Aug-2014]	20-Feb-2014	Non-Provisional in KP006 family	US9,353,123 on 31-May-2016	ISSUED
KP012.AWO	PCT/US2014/063630 (PCT Int1) [Pub'd as WO2015/066584 on 7-May-2015]	3-Nov-2014*	PCT (claims benefit of KP006.B/USPR, & KP006.C/US)		EXPIRED/ IN NATIONAL STAGE
KP012.A/AU	2014/341966 (Australia) [Pub'd as AU2014341966 on 12-May-2016]	3-Nov-2014	Nat'l Stage of KP012.AWO	AU2014341966 on 30-Nov- 2017	GRANTED

KP011.E/JP2	2018-199914 (Japan)	31-Oct-2014	DIV of KP011.E/JP		ABANDONED
KP011.E/KR	10-2016-7014146 (Korea)	31-Oct-2014	National Stage of KP011.E/WO		ABANDONED
	[Pub'd as KR20160099084				
	on 19-Aug-2016]				
KP011.E/MX	MX/a/2016/005668 (Mexico)	31-Oct-2014	National Stage of KP011.E/WO	MX355330 on 16-Apr-2018	GRANTED
	[Pub'd as MX2016005668 on				
KP011.E/NZ	719185	31-Oct-2014	National Stage of KP011.E/WO	NZ719185 on 27-Feb-2018	GRANTED
	(New Zealand)		,		
	[Pub'd as NZ719185 on 24-				
	Nov-2017]				

Ω	TITLE(S)) CRY Assignee Kala	PATENT FAMILY: KP013
<u> </u>	ĕ ≓	4
	Le im	ш
ñ	<b>∮</b> 00	3
OUR REF NO		-11
2	80	₽
•	5 29	<b>S</b>
	6	
		₹.
	<u> </u>	4
		€.
	Z.	9
	<u> </u>	₩.
	Ö	
	20	
	5	
	, v	
	¥.	
22	16	
- 5	4	
F.	<b></b>	
	121	
至	3≽	
///// <b>////////////////////////////////</b>	<b>)</b>	
///// <b>////////////////////////////////</b>	[ <u> </u>	
APPL'N NO. & COUNTRY	<b>3</b>	
	( O	
	( O	
	<b>9</b>	
	<b>*</b>	
<i></i>	Ø	
	<b>S</b>	
	fi.	
	<b>1</b>	
	Z.	
	9	
	<b>S</b>	
//////// <del>//</del>	TITLE(S)). CRYSTALLINE FORMS OF A THERAPEUTIC COMPOUND AND USES THEREOF Assignee. Kalia	
FILING DATE	( G	
	₩ #	
ଦ	南	
0	<b>70</b>	
35	<u></u>	
	Yn Yn	
<u></u>		
FAMILY REL'P		
Ü		
<b>70</b>		
	1	
- A	<b>Y</b>	m
	•	
<b>Z</b>		
TENT		
-		
-		
-		
-		
-		
-		
NO. & ISSUE DATE		
NO. & ISSUE DATE		
NO. & ISSUE DATE		
-		
NO. & ISSUE DATE		

*NOTE: 11/1/2014 was a Saturday	KP012.A/US2	KP012.A/US	KP012.A/JP2	KP012.A/JP	KP012.A/HK-EP	KP012.A/EP	KP012.A/CA2	KP012.A/CA
Saturday	15/604,080 (United States) [Pub'd as US2017/0260193 on 14-Sep-2017]	15/032,595 (United States) [Pub'd as US2016/0257693 on 8-Sep-2016]	2018-199872 (Japan)	2016-552430 (Japan) [Pub'd as JP2016535779 on 17-Nov-2016]	17102022.9 (Hong Kong) [Pub'd as HK1228278 on 03- Nov-2017]	14857110.2 (European Patent Office) [Pub'd as EP3062795 on 07- Sep-2016]	3109285 (Canada)	2,928,665 (Canada) [Pub'd as CA2928665 on 07- May-2015]
	24-May-2017	3-Nov-2014 (27-Apr-2016 (371 Date))	3-Nov-2014	3-Nov-2014	23-Feb-2017	3-Nov-2014		3-Nov-2014
	CON KP012.A/US	Nat'l Stage of KP012.A/WO	DIV of KP012.A/JP	Nat'l Stage of KP012.A/WO	HK Registration of KP012.A/EP	Nat'l Stage of KP012.A/WO	DIV of KP012.A/CA	Nat'l Stage of KP012.A/WO
	US 9,890,173 on 13-Feb-2018	US 9,688,688 on 27-Jun-2017		JP6426195 on02-Nov-2018				
	ISSUED	ISSUED	ABANDONED	GRANTED	PENDING (Published)	PENDING (Published)	In Progress	ABANDONED

PATENT FAMILY: KP014					
TITLE(S)) A spec UREA DERIV	THLE(S)): A spec UREA DERIVATIVE AND USES THEREOF, B spec. 1:AMINO:TRIAZOLO(15-A)PYRIDINE-SUBSTITUTE UREA DERIVATIVE AND USES THEREOF	1.AMINO-TRIAZOLO(1.5.A)PYRI	DINE SUBSTITUTE UREA DERIVAT	IVE AND USES THEREOF	
	SOME THE PROPERTY OF THE PROPE	7111100 71441	Transmitted to	3 4 4 11 11 11 11 12 12 12 12 12 12 12 12 12	74 44 177
CONTRET INC	ACTURED & COURTER	FILLING DATE	FAMILI SELF	PATENT NO STOCKE DATE	32.00
KP014.A/USPR	62/090,045 (United States)	10-Dec-2014	Provisional 1		EXPIRED
KP014.BWO	PCT/US2015/065076 (PCT Int'l) [Pub'd as WO2016/094710 on 16-Jun-2016]	10-Dec-2015	PCT of KP014.B/USPR		EXPIRED/ IN NATIONAL STAGE
KP014.B/AU	2015-360,438 (Australia) [Pub'd as AU2015360438 on	10-Dec-2015	Nat'l Stage of KP014.B/WO	AU2015360438 on 24-Jan-2019	GRANTED
	15-Jun-2017]				
KP014.B/CA	2969467 (Canada)	10-Dec-2015	Nat'l Stage of KP014.B/WO		PENDING (Published)
	[Pub'd as CA2969467 on 16- Jun-2016]				
KP014.B/EP	15814003.8 (European Patent Office)	10-Dec-2015	Nat'l Stage of KP014.B/WO	EP3230272 on 19-Aug-2020	GRANTED
	[Pub'd as EP3230272 on				

KP013.B/US	KP013.B/WO	KP013.A/USPR
15/529,969 (United States) [Pub'd as US 2017/0313724 on 2-Nov-2017]	PCT/US2015/062491 (PCT Int'l) [Pub'd as WO2016/086026 on 2-Jun-2016]	62/084, 682 (United States)
25-May-2017	24-Nov-2015	26-Nov-2014
Nat'l Stage of KP013.BWO	PCT of KP013.A/USPR	Provisional 1
US 10,253,045 on 09-Apr-2019 ISSUED		
ISSUED	EXPIRED/ IN NATIONAL STAGE	EXPIRED

KP015.A/USPR	OUR REF. NO	Assignee Kala	PATENT FAMILY: KP015 TITLE(S)) CRYSTALLINE (
			7: KP015 TALLINE FORMS
62/385,155 (United States)	APPLINING & COUNTRY		PATENT FAMILY: KP015 TITLE(S)) CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
,155 ates)	COUNTRY		IC COMPOUNDS
8-Sep-2016	FILING DATE		AND USES THER
2016	DATE		EOF
Provisional 1	FAMILY REL'P		
	PATENT NO & ISSUE DATE		
EXPIRED	STATUS		

KP014.B/EP-DE	(Germany)		Validation of EP3230272		
KP014.B/EP-FR	(France)		Validation of EP3230272		
KP014.B/EP-GB	(Great Britain)		Validation of EP3230272		
KP014.B/HK-EP	18104975.1 (Hong Kong) [Pub'd as HK1245274 on 24- Aug-2018]	17-Apr-2018	HK Registration of KP014.B/EP		To Be Abandoned
KP014.B/US	15/534,448 (United States) [Pub'd as US2018/0057489 on 01-Mar-2018]	8-Jun-2017	Nat'l Stage of KP014.B/WO	US10,174,022 on 08-Jan-2019	ISSUED
KP014.B/US2	16/204,827 (United States) [Pub'd as US2019/0092772 on 28-Mar-2019]	29-Nov-2018	CON of KP014/B/US	US10,875,857 on 29-12-2020	ISSUED
KP014.B/US3	17/112,542 (United States) [Pub'd as US2021/0087192 on 25-Mar-2021]	04-DecDe, 2020	CON of KP014/B/US2		PENDING (Published)

KP015.A/US	15/694,252	1-Sep-2017	US ORD of KP015.A/USPR	US 10,336,767 on 2-Jul-2019	ISSUED
	(United States) [Pub'd as US2018/0065977 on 08-Mar-2018]				
KP015.A/US2	16/415,848 (United States)	17-May-2019	DIV of KP015.A/US	US 10,626,121 on 21-Apr-2020	ISSUED
	[Pub'd as US2019/0270752 on 05-Sep-2019]				
KP015.A/US3	16/818,033	13-Mar-2020	CON of KP015.A/US2		PENDING (Allowed)
	(United States) [Pub'd as US2020/0216460 on 09-Jul-2020]				
KP015.A/WO	PCT/US2017/049914	1-Sep-2017	PCT Int'l of KP015.A/USPR		EXPIRED/ IN NATIONAL
	(PCL Intl) [Pub'd as WO2018/048746 on 15-Mar-2018]				- SI AGE
KP015.A/AU	2017324251 (Australia)	1-Sep-2017	Nat'l phase of KP015.AWO		ABANDONED
KP015.A/AU2	202017446	1-Sep-2017	DIV of KP015.A/AU		PENDING
	(Australia)				
KP015.A/BR	BR112019004463.9 (Brazil)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING
KP015.A/CA	3036065 (Canada)	1-Sep-2017	Nat'l phase of KP015.A/WO		PENDING
KP015.A/CN	201780055105.9 (China)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING
KP015.A/EP	17849362.3 (Europe)	1-Sep-2017	Nat'l phase of KP015.AWO		PENDING
KP015.A/EP-HK	62019000441.1 (Hang Kang)	26-Dec-2019	HK registration of KP015.A/EP		PENDING
KP015.A/JP	2019-513002 (Japan)	1-Sep-2017	Nat'l phase of KP015,AWO		PENDING

KP017.B/WO	KP017.A/USPR	OUR REF. NO	Assignee: Kala	TITLE(S)) BIOCHEMICAL	PATENT FAMILY: KP017
PCT/US2018/056751 (PCT) [Pub'd as WO2019079747 on 25-Apr-2019]	62/575,280 (United States)	APPLINIO & COUNTRY		TITLE(S)). BIOCHEMICAL BINDING OF RET9 AND VEGER2 INHBITORS	
19-Oct-2018	20-Oct-2017	FRING DATE		TORS	
PCT of KP017.A/USPR	Provisional 1	FAMILY RELP			
		PATENT NO. & ISSUE DATE STATUS			
PENDING (Published)	PENDING	STATUS			

KP015.C/US	15/694.383	1-Sep-2017	US ORD of KP015.C/USPR	US10,392,399 on 27-Aug-2019	ISSUED
	(United States)				
	[Pub'd as US2018/0065979				
	on 08-Mar-2018]				
KP015.C/US2	16/513,505	16-Jul-2019	DIV of KP015.C/US	US10,766,907 on 08-Sep-2020	ISSUED
	(United States)[Pub'd as				
	US2019/0337963 on 07-Nov-				
	2019]				
KP015.C/WO	PCT/US2017/049931	1-Sep-2017	PCT Int'l of KP015.C/USPR		EXPIRED/ IN NATIONAL
	(PCT Int'l)				STAGE
	[Pub'd as WO2018/048750				
	on 15-Mar-2018]				
KP015.C/AU	2017324716	1-Sep-2017	Nat'l phase of KP015.C/WO	AU2017324716 on 26-Nov-	GRANTED
	(Australia)			2020	
KP015.C/CA	3036340	1-Sep-2017	Nat'l phase of KP015.C/WO		PENDING
	(canada)				
KP015.C/EP	17849365.6	1-Sep-2017	Nat'l phase of KP015.C/WO		PENDING
	(Europo)				

KP017.B/NZ	KP017.B/MX	KP017.B/KR	KP017.B/JP	KP017.B/IN	KP017.A/EP-HK	KP017.B/HK-CN	KP017.B/EP	KP017.B/CN	KP017.B/CA	KP017.B/BR	KP017.B/AU
763580 (New Zealand)	Mx/a/2020/007183 (Mexico)	10-2020-7014314 (South Korea)	(Japan) 2020-521977 (Japan)	202017017553 (India)	62021026025.8 (Hong Kong)	62021024397.3 (Hong Kong)	EP18801107.6 (Europe) [Pub'd as EP3697775 on 26- Aug-2020]	201880080672.4 (China) [Pub'd as CN11465601A on 28-Jul-2020]	3079673 (Canada)	BR1120200077879 (Brazil)	2018351520 (Australia)
19-Oct-2018	19-Oct-2018	19-Oct-2018	19-Oct-2018	19-Oct-2018	20-Feb-2021	27-Jan-20121	19-Oct-2018	19-Oct-2018	19-Oct-2018	19-Oct-2018	19-Oct-2018
Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	HK of KP017.A/EP	HK of KP017.B/CN	Nat'l phase of KP017.BWO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO	Nat'l phase of KP017.B/WO
PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING	PENDING

OUR REF NO	TITLE(S)) PARTICLES OF Assignee Kaia
	PALENI PANI TITLE(S)) PAR Assignee Kala
	9 m n
22	8 7 2
**	
	>
<b>5</b>	9 × 5
	*** 23 7
	-
	¥
	m <b>z</b>
	2
	27
	¥
	75
	( O
	₩.
	7
>	<b>.</b>
	G5
	25-
2	Z
74	<u>~</u>
0	备
00	<b>.</b>
- 6	<b></b>
6	l H
	l ő
APPL'N NO & COUNTRY	<u> </u>
70	9
	2
	ATENI FAMILIT - KAUTS ITLE(S)): PARTICLES, COMPOSITIONS AND METHODS FOR OPTHLAMIC AND/OR OTHER APPLICATION ISSIGNEE KAIA
	( <del>-</del> <del>-                                </del>
	<b>)</b>
	[ <u>\$</u>
	Ŋ
<u></u>	i fi
<u> </u>	<b>*</b>
á	<b>5</b> 5
<u> </u>	
5	<u> </u>
FILING DATE	<b>.</b>
	<b>(</b>
	<b> </b> 35
	<u>1</u>
	ľ
	( 5
	<b>)</b>
	<b> </b>
290	9
	ទី
	l
W	<b>(</b>
	<b>[</b>
<b>III</b>	1
FAMILY REL'P	
<b>(1)</b>	<b>(</b>
	<b> </b>
	1
	1
<i></i>	<b> </b>
	<b>[</b>
<u> </u>	
<b>*************************************</b>	
////////50	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Con	
<b>8</b> H	<b>!</b>
Se SS	<b>V</b>
NO & ISSU	666666666666666666666666666666666666666
& ISSUE	
& ISSUE DA	
& ISSUE DAT	
& ISSUE DATE	
& ISSUE DATE	
& ISSUE DATE	
& ISSUE DATE S	
A ISSUE DATE ST.	
& ISSUE DATE STATE	
&ISSUEDATE STATU	
&ISSUE DATE STATUS	
&ISSUEDATE STATUS	
&ISSUEDATE STATUS	
&ISSUE DATE STATUS	
&ISSUEDATE STATUS	
&ISSUE DATE STATUS	
EDATE STATUS	
EDATE STATUS	
. & ISSUE DATE STATUS	
& ISSUE DATE S	

PATENT FAMILY KP018	PATENT FAMILY: KP018  THE FAN PARENCES OF MERCENTIONS AND METHODS FOR OPTHE AMOUND OTHER ADDITIONS	HI MICHARD CHITCH AND HIS	ATIONS		
Assignee Kala					
OUR REF NO	APPLNING & COUNTRY	FILING DATE	FAMILY RELIP	PATENT NO. & ISSUE DATE	STATUS
KP018.A/USPR	62/395,980 (United States)	16-Sep-2016	Provisional 1		EXPIRED
KP018.B/WO	PCT/US2017/051866 (PCT Intl) [Pub'd as WO2018/053318 on 22-Mar-2018]	15-Sep-2017	PCT of KP018,A/USPR		EXPIRED/ IN NATIONAL STAGE
KP018.B/US	16/331,472 (United States) [Pub'd as US2019/0216824 on 18-Jul-2019]	07-Mar-2019	Nat'l phase of KP018.B/WO		ABANDONED
KP018.B/CA	3037174 (Canada)	15-Sep-2017	Nat'l phase of KP018.B/WO		To Be Abandoned

KP017.B/US

16/757,305 (United States)

17-Apr-2020

Nat'l phase of KP017.B/WO

PENDING

Assignee: Kala TITLE(S)) PARTICLES, COMPOSITIONS AND METHODS FOR OPTHLAMIC AND/OR OTHER APPLICATIONS

PATENT FAMILY KP023

14 625.70	KP022 A/WO	THE(S) PARTICLES COMPO Assigned Kala OUR REF. NO	DATEM CAMILY KD022
(PCT Int'l) (PCT Int'l) [Pub'd as WO2019/055028 on 21-Mar-2019]	PCT/HS2017/051873	APPLINING & COUNTRY	
10,000,001	15-Sen-2017	TRILE(S)) PARTICLES COMPOSITIONS AND METHODS FOR OPTHLAMIC AND/OR OTHER APPLICATIONS Assignes: Kala  GUR REF. NO APPLIA NO & COUNTRY FILING DATE FAN	
10.10	none	FAMILY RELP	
		PATENT NO & ISSUE DATE STATUS	
הראקט טוארט מיייייייייייייייייייייייייייייייייייי	ARANDONED	STATUS	

NTO 18. B/CA	KP019.B/US	KP019.BWO	KP019.A/USPR
(Canada)	16/331,474 (United States) [Pub'd as US2019/0216726 on 18-Jul-2019]	PCT/US2017/051869 (PCT Int'I) [Pub'd as WO2018/053321 on 22-Mar-2018]	62/395,984 (United States)
13-5eb-2017	07-Mar-2019	15-Sep-2017	16-Sep-2016
Nati priase di NEO 13. B/WO	Nat'l phase of KP019.B/WO	PCT of KP019.A/USPR	Provisional 1
To be Abandoned	ABANDONED	EXPIRED/ IN NATIONAL STAGE	EXPIRED

		× 11
9	×	- 72 ≒ <b>≯</b>
22	70	S III
5	2	- 6 m <b>≠</b>
≰	· · · · · · · · · · · · · · · · · · ·	®
ા ડ	<u></u>	PATENT FAMI TITLE(S) Oct Assignee Kala
KP025.A/USPR	OUR REF NO	PATENT FAMILY KP025 TITLE(S) Ocular Therapies Assignee' Kala
_ ~		₩ 💆
		7 🛪
		<b>3</b> 3
		₩ N
		ěř.
0.6		
63/027,218 (United States)		
# 2	70	
,7 1.5		
St: 278	<b>**</b>	
# 3	• •	
(S)	20	
	Ω	
	APPL'N NO & COUNTRY	
	<b>2</b>	
	<b>70</b>	
	<b>*</b>	
19-May-2020	FILING DATE	
ż	<b>#</b>	
a¥	<b>5</b>	
2	<b>P</b>	
	m	
Provisional	FAMILY REL'P	
,,		
∺.		
na	70	
_	<b>P</b>	
	<b>15</b>	
	-	
	Þ	
	<b>7</b>	
	5	
	20	
	<b>77</b>	
	, vi	
	10000000000000000000000000000000000000	
	m	
	m	
	E DA	
	EDATE	
	EDATE	
	EDATE	
T1	EDATE	
PE	EDATE ST	
PEND	EDATE STAT	
PENDIN	EDATE STATUS	
PENDING	PATENT NO & ISSUEDATE STATUS	
PENDING	EDATE STATUS	
PENDING	EDATE STATUS	
PENDING	EDATE STATUS	
PENDING	EDATE STATUS	
PENDING	EDATE STATUS	
PENDING	EDATE STATUS	
PENDING	EDATE STATUS	
PENDING	EDATE STATUS	

KP023/24.B/US	KP024.A/USPR	OUR REF. NO	PATENT FAMILY KP024 TITLE(S)) PARTICLES CON Assignee Kala
16/502,635 (United States) [Pub'd as US2020-0016084 on 16-Jan-2020]	62/694,819 (United States)	APPL'N NO & COUNTRY	PATENT FAMILY: KP024 TITLE(S)) PARTICLES, COMPOSITIONS AND METHODS FOR OPTHLAMIC AND/OR OTHER APPLICATIONS Assignee Kala
03-Jul-2019	6-Jul-2018	FILING DATE	THLAMIC AND/OR OTHER APPLICA
US ORD Filing of KP23.A/USPR & KP024.USPR	Provisional	FAMILY RELP	ATIONS
		PATENT NO & ISSUE DATE STATUS	
ABANDONED	EXPIRED	STATUS	

KP023.A/USPR	OUR REF. NO
62/694,805 (United States)	APPLNING & COUNTRY
6-Jul-2018	FILING DATE
Provisional	FAMILY RELP
	PATENT NO. & ISSUE DATE
EXPIRED	STATUS

	KP027 A/USPR		CON NO. 140	5			Toolyline Maid		Ī		1	1	
	≥		Í				n	•			1		1
	Ş		ā	5			a	S S		5	,	3	Š
'	~			*						9		•	<
										3	1		S
										ÿ		•	3
				▓						D			4
				▓									*
	5												
(United States)	63/136 045		AFFECTIVE OF COCKETS	9									
S Pe	<u>က</u>												
tate	5		Ĉ	3									
(s)			Q	o S									
			Ę	2									
				i									
	$\dashv$												
	11-,Jan-2021												
	3		č	Š									
	રુ		Ş										
	_		'n	ij									
				▓									
				*									
				*									
				▓									
;	Ŗ			ij									
	<u></u>												
	Provisional		3	á									
			PARTY NEED	4									
				▓									
				░									
				*									
				*									
				9									
			i	1									
			Ž	1									*
			ŧ	3									
			2										
			ě	á									
			PAIRNI NO GIOGOPPIAIR										
			ř										
			017100										
!	PENDING		Š										
	Ĭ		ç	0									
'	۱,۱												
1				▓	ø					8	8	8	8
	F	***	***	93	ø	w			8	ø	×	ø	≫

KP026.A/USPR	PATENT FAMILY: KP026 TITLE(S): Coular Therapies Assignee: Kala  OUR REF. NO
63/027,226 (United States)	APPL'NING & COUNTRY
19-May-2020	FILING DATE
Provisional	FAMILY RELP
	PATENT NO & ISSUE DATE STATUS
PENDING	STATUS

## EXHIBIT C

## Trademarks

() <b>X</b>	6	<b>5</b> 7 7
Juit ME	, ž	FAMIII DESCR
KTM001/US (United States)	OUR REF. NO	KALA FAMILY: DESCRIPTION:
/US	7	Y:
S)	ō	9
		•
		27 7
		pha T
85/	2	TEN.
85/932,177	APPL'N NO.	KTN1001 TYPE: Research and development of pharmaceuticals and de
177	3	leve icals
		lops and
		nen 1 dn
		15 SC 1
14	#	Vice X
-Ma	Z	SERVICE MARK rvices and technica formulation technol
14-May-2013	FILING BATE	d tec
)13	-	
		K I NIOO I XFE: SERVICE MARK Research and development services and technical co of pharmaceuticals and drug formulation technology
		ons
42	_	ultat
	7	ion
	5	relat
	INT'E CLASS	ing
	Ĭ,	to th
		K [M00] TYPE: SERVICE MARK  Research and development services and technical consultation relating to the development and so of pharmaceuticals and drug formulation technology
		velo
	Ã	hue
4,58	, 7	e tuc
4,585,580	REGISTRAT NO.	ınd s
õ	<b>3</b>	MARK
		MARK: tentific testin
		: tesi
	2	ing
12.		
12-Aug-1	ZĦ	
g-14	REGISTRATIO DATE	
	9	
R		
REGISTEREL	22	<b>₹</b>
STE		<u> </u>
RE]	) Vin	À
D		

2	$\mathbf{z}$		
Ħ.			ラミン
ī	S	2	KALA FAMIII DESCR
(United States)	KTM002/US	OUR REF. NO	KALA FAMILY: DESCRIPTION
121	$\overline{}$	7	Y:
es)	S	2	×
_		- <del>-</del>	Ž
			**
			면 # <b>*</b>
			KTM002 As amended 12/inflammatory displarmaceuticals
	85	-	
	/93		ii to to
	85/932,175	APPL'N NO	53 T 2
	17	2	dis 2)/:
	O	- P	T) %1
			SC: T
			KTM002 TYPE: As amended 12/5/17 Pl inflammatory diseases; d pharmaceuticals
			la:
			9 C
			문중
	4		2. E
	₹		7 <u>0</u>
	ĺау		R PR
	2		GI A
	14-May-2013	FILING DATE	KTM002 TYPE: TRADEMARK (character mark)  MARK: As amended 12/5/17. Pharmaceutical preparations for use in the treatment of ophthalmological diseases and inflammatory diseases; drug delivery agents in the form of a coating for active ingredients of a pharmaceutic pharmaceuticals
	S	<b>**</b>	M. an
			AR On
			i s
			(c)
			10
		-	ас 1 а
		-	0 ± 5
	$\odot$	•	m an
	005	2	311 311
			atu fo
		INT'L CLASS	ne:
			tt (
			ές τ
			in in
			nth gre
		REGISTRATIO NO	alı dı
	S	<b>₽</b>	110 2111
	5,401,810		S C W
	Ę	6#	MARK logical s of a j
	81		552
	0		iis
			1111
			Ę Š
			5 E
			<del>-</del>
	_		Ď
	13-Feb-18	REGISTRATION DATE	5
	E	2 4	111
	<u>-</u>	<b>#</b>	<del>-</del>
	00		th
		- S	3 <u>d</u>
			2
			ć.
			2
			2,
	$\nabla$		2 ¥
	E		
	SI		<u> </u>
	Ħ	STATES	KALA ide range
	REGISTEREL		KALA uses and naceutical to facilitate the delivery of a wide range of
	日		94
	_		

KTM003/EUTM (European Union)	KTM003/CA (Canada)	KTM003/US (United States)	FAMILY: DESCRIPTION: OUR REF. NO	,
017603739	1873402	87/492,686	Topical ophit	
15-Dec-2017	15-Dec-2017	16-Jun-2017	ralmic pharmaceutical prep	スキにはよる
005	005	005	Topical ophthalmic pharmaceutical preparations: topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye  NO FILING DATE INT'L CLASS REGISTRATION REGISTRATION STA	
017603739	TMA1,067,229	5,722,929	MARK: c pharmaceutical preparat REGISTRATION NO.	
08-Mar-2019	23-Dec-19	09-Apr-19	ons for post-surgical treat  REGISTRATION  DATE	
REGISTERED	REGISTERED	REGISTERED	ient of the eye	

KTM003/Brexit (EU/UK) KTM003/MX	UK00917603739 1986895	15-Dec-2017 15-Dec-2017	005	UK00917603739 1860084	08-Mar-2019 15-Dec-17	REGISTERED REGISTERED
KTM003/MX (Mexico)	1986895	15-Dec-2017	5	1860084	15-Dec-17	REGISTERED
KTM003/CN (China)		29-Apr-2020	5			ALLOWED
						•

· ·	KTM004 TYPE: Topical ophthalmic pharm APPL'N NO. 87/492,692 1873400 017604083	TRADEMARK (character mark) accunical preparations: topical ophth  FILING DATE  INT  16-Jun-2017  15-Dec-2017  15-Dec-2017		MARK: ical preparations for pos REGISTRATION NO.  TMA1,085,451 017604083	ARK:  DI POSI-SUIZECAL ITCAHINENT OF the eye  DATE  11 20-Oct-20  2-May-18	
	1873400	15-Dec-2017	N/A	TMA1,085,451	20-Oct-20	
<u> </u>	017604083	15-Dec-2017	005	017604083	2-May-18	
KTM004/Brexit (EU/UK)	UK00917604083	15-Dec-2017	005	UK00917604083	2-May-18	
KTM004/MX	1986902	15-Dec-2017	005	1860087	15-Dec-17	

KTM005/US (United States) KALA OUR REF. NO DESCRIPTION: FAMILY: Topical ophilialmic plarmaceutical preparations, topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye KTM005 TYPE: APPL'N NO. 87/492,700 TRADEMARK (character mark) FILINGDATE 16-Jun-2017 INTIL CLASS 005REGISTRATION NO. MARK: REGISTRATION LORPRENIO ABANDONED STATES

KTM006/US (United States)	OUR REP. NO		KALA FAMILY: DESCRIPTION:	(Mexico)	KTM005/MX	(EU/UK)
87/492,704	APPL'N NO.	100000000000000000000000000000000000000	KTM006 TYPE:		1986896	
16-Jun-2017	FILING DATE	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	TRADEMARK (character mark)		15-Dec-2017	
005	INTL CLASS		KTM006 TYPE: TRADEMARK (character mark)  MARK:  Toward onlithalmic reliarmacentical preparations, tomical onlithalmic pharmacentical preparations for the treatment of dryness of the eye.		005	
	FAMILY REL'P		MARK:		1860085	
	REGISTRATION DATE		reatment of diviness of the		15-Dec-17	•
ABANDONED	STATUS	4.	SUVEOUS		REGISTERED	

(United States)
KTM007/CA

KTM007/US

87/492,707

16-Jun-2017

005

1873393

15-Dec-2017

005

TMA1,066,022

11-Dec-19

REGISTERED

ABANDONED

(Canada)

KTM007/EUTM
(European Union)

KTM007/Brexit

UK00917604059

15-Dec-2017

005

UK00917604059

2-May-2018

REGISTERED

017604059

15-Dec-2017

005

017604059

2-May-2018

REGISTERED

OUR REF. NO

APPL'N NO.

FILING DATE

INT'I CLASS

REGISTRATION

REGISTRATION

STATES

DATE.

KALA
FAMILY:
DESCRIPTION:

KTM007

TYPE:

TRADEMARK (character mark)

Topical ophthalmic pharmaceutical preparations: topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye

MARK:

VISOOVA

UK00917604067 017604067 1873388 15-Dec-2017 15-Dec-2017 15-Dec-2017 005 005 N/A UK00917604067 TMA1,066,019 017604067 2-May-18 2-May-18 11-Dec-19 REGISTERED REGISTERED REGISTERED

KTM005/CA (Canada)

KTM005/EUTM
(European Union)
KTM005/Brexit

KALA FAMILY: DESCRIPTION:	KTM008 TYPE:  Pharmaceutical preparatio	TRADEMARK (character mark) us and substances for the treatment o	icier mark) treatment of ophthalmologi	MARK:	KTM008 TYPE: TRADEMARK (character mark)  EYSUVI  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders, topical ophthalmic pharmaceutical	EYSUVIS mic pharmaceutical
OF REFERE	preparations, topical ophti	alinic pharmaceutical pre	preparations topical ophthalmic pharmaceutical preparations for the treatment of dryness of the comparations for the treatment of dryness of the comparations.	of dryness of the eye	RECONTRATION	\$ <del>    4</del>   5
				NO	DATE	
KTM008/US	87/694,659	22-Nov-2017	005	6,301,667	23-Mar-2021	REGISTERED
(United States)						
UA/800MTM	1927808	18-May-2018	500	1927808	29-Aug-2018	REGISTERED
(Auralia)						
KTM008/CA	1899974	18-May-2018	N/A	TMA1,080,021	25-June-2020	REGISTERED
(Canada)						
KTM008/CN	31025579	21-May-2018	005	31025579	13-Apr-2019	REGISTERED
(Cinina)	017007002	18 May 2018	2005	017002003	25 Cont 2018	DECIGERATE
(European Union)	01/302333	10-May-2010	000	01/202223	25-3cpt-2010	NEOLO LENED
KTM008/Brexit	UK00917902993	18-May-2018	005	UK00917902993	25-Sept-2018	REGISTERED
(EU/UK)						
AL/800MLM	2018-66101	21-May-2018	500	6088912	12-Oct-2018	REGISTERED
(Japan)						
KTM008/MX	2049861	18-May-2018	005	1932976	08-Oct-2018	REGISTERED
(Mexico)						
KTM008/KR	40 2018 67794	18-May-2018	005	40 1457280	12-Mar-2019	REGISTERED
(Korea)						
KTM008/CH	78781/2018	18-Sep-2018	5 00	727020	06-Feb-2019	REGISTERED
(Switzerland)						
MU/800MLM	UK00003311937	18-May-2018	500	UK00003311937	08-17-2018	REGISTERED
(United Kingdom)						

KTM007/MX (Mexico)

1986899

15-Dec-2017

005

1860086

15-Dec-2017

REGISTERED

$\supset$	×	OUR REF NO	KALA FAMII DESCR
Ħ.	J		- S ≥ ≥
E E	₫	<b>3</b>	QA,
(United States)	KTM009/US	₩.	KALA FAMILY: DESCRIPTION:
ate	$\mathbf{S}$		
<u>.</u>		ō	9
			7
			pi Pi
			cp:
	000	<b>2</b>	Na Na
	7/6		00 100
	87/694,665		5. E.S.
	66	2.	III II To
	O	APPL'N NO	T) Dic.
			PI il c
			KTM009 TYPE:  Pharmaceutical preparations a preparations, Topical ophthalit
			illa Tha
			T and land
	22		CP PSI
	22-Nov-2017	FILING DATE	KTM009 TYPE: TRADEMARK (character mark)  M  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular disea preparations. Topical ophthalmoc pharmaceutical preparations for the treatment of dryness of the co
	-VC		
	20]	3	AR FCC
	7	#	E G
			ch al
			ara e ti
			cie par
			atio
			ark m:
	0	#	) of a for
	20	INT'L CLASS	ф: dq
			tha c tr
		, i	line Cart
			olc
			H C
			ul a of d
		*	nd ind
		REGISTRATIO NO	OCI
		2 4	ılar s of
		~ 7	th:
		#	es 🗷
		<b>9</b>	e se 🕏
			# ₹
			<b>6</b> 7
		<b>75</b>	īšo
			lde
			15
		STRATIO	top
			άg
			101
			Jihiti
			ha h
			THC.
			p <del>i</del>
	➣		
	ALLOWED		ARK: ZUDREYA ses and disorders, topical ophthalmic pharmaceutical se
	Ŏ	STATUS	ű Y
	¥Ε		i 🗲
	Ú		- 2
			>
			Ţ.

<b>7</b>	OUR REF. NO	KALA FAMILY: DESCRIPTION:
E E		FAMII DESCR
[₹ 		^ ≤ F
		2 F *
KTM010/US (United States)		KALA FAMILY: DESCRIPT
ies i		E.
$\overline{}$		¥
		<b>57 -</b>
		₫ 👸 🖍
8	-	
76		)   CH
94		* 5 <b>-</b>
87/694,667	APPL'N NO.	KTM010 TYPE:  Pharmaceutical preparation preparations: Topical opitth
7		ore of
		YP al
		epra 🕏
		## @ ##
		<u>15</u> 5.
22		C S Z
, ,		
\ [0\		
-2		B
22-Nov-2017	FILING DATE	E S R
7		<u>5</u> 9
		11.0 11.0
		장 요 유
		TRADEMARK (character mark) and substances for the treatment o think pharmaceutical preparations i
		\$ <u>0</u>
005		0 0
5		문
	INT'L CLASS	KTN1010 TYPE: TRADEMARK (character mark)  MA  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseas preparations. Topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye
		12 C
		単幅
		열 원
		<u></u>
		<u></u>
		š či
	REGISTRATIC	오 등
		<b>5</b> 6.
		se: =
		ĭa sa ≩
		e es a
		₩
		₫.
		8
		Ģ.
		Š
		8
		ğ
	REGISTRATION DATE	<u> </u>
		<b>£</b>
		<u>5</u>
		₽.
		<u>6</u>
		ž un
$\triangleright$		
ALLOWED		SOODR ses and disorders, topical ophthalmic pharmaceutical c
Ó		
₩		₹ <b>≚</b>
H		- ×
_		SOODRY. <sup>A</sup>
		-
	00000000	

FAMILY:  DESCRIPTION: Pharmaceutical preparations and substances for the treatment of inflammation and pain pharmaceutical preparations and substances for the treatment of inflammation and pain pharmaceutical preparations and substances for the treatment of surgical treatment of the eye  OUR REF. NO  APPLIN NO.  PRIENCE DATE  INTLICLASS  RECISTRATION  REGISTRATION  INTLICLASS  RECISTRATION  REGISTRATION  REGISTRATION  REGISTRATION  STATUS					
		***************************************	*********	***********	*********
	- 6			•	• 🕶
				<b>.</b>	
				un =	
<u>.</u>	-				
<u>.</u>	- F				
<u>.</u>	<b>11</b>			70 +	₹
<u>.</u>				■ .	
<u>.</u>				0	
				2	
HAPLYNO FILING DATE INTICIASS REGISTRATION REGISTRATION TELITYS logo  APPLYNO FILING DATE INTICIASS REGISTRATION REGISTRATION TAILS				• •	
HAPLYNO FILING DATE INTECASES REGISTRATION REGISTRATION (B&W Eye Design)  APPLYNO FILING DATE INTECASES REGISTRATION REGISTRATION (B&W Eye)  APPLYNO FILING DATE INTECASES REGISTRATION REGISTRATION (B&W Eye)  INVELTYS logo (B&W Eye)  Design)  REGISTRATION REGISTRATION (B&W Eye)  STATUS					
NTMOIL TYPE: TRADEMARK (design plus words; letters &/or MARK: (B&W Eye (B&W Eye (B&W Eye (B&W Eye (B&W)))))  Pharmaceutical preparations and substances for the treatment of inflammation and pair; pharmaceutical preparations and substances for the treatment of ophthalmic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye  APPLYNOO FILING DATE FOTL CLASS RECISIBATION REGISTRATION STATUS					
TRADEMARK (design plus words, letters &/or   INVELTYS logo (B&W Eye   Design)    harmaccutical preparations and substances for the treatment of inflammation and pain, pharmaceutical preparations and substances for the treatment of phthalmic pharmaceutical preparations and substances for the treatment of phthalmic pharmaceutical preparations topical ophthalmic pharmaceutical preparations for post- ingical treatment of the eye			8 O	של	-
INVELTYS logo mumbers  MARK  (B&W Eye  Besign plus words, letters &/or  MARK  (B&W Eye  CBAN Eye			# P.	₹	<b>*</b> *
MO11 TYPE: TRADEMARK (design plus words, letters &/or MARK: (B&W Eye R&W Eye numbers (B&W Eye R&W Eye))  macentical preparations and substances for the treatment of inflammation and pain; pharmacentical preparations and substances for the treatment of almological and ocular diseases and disorders; topical ophthalmic pharmacentical preparations; topical ophthalmic pharmacentical preparations topical ophthalmic pharmacentical preparations for post-rad treatment of the eye  APPLY NO BILING DATE INTEGRASS REGISTRATION REGISTRATION STATES			₩. 🖹	ā	
INVELTYS logo mumbers  MARK  (design plus words, letters &/or  MARK  (B&W Eye  B&W Eye  Design)  certical preparations and substances for the treatment of inflammation and pain pharmaceutical preparations and substances for the treatment of mological and ocular diseases and disorders, topical ophthalmic pharmaceutical preparations iopical ophthalmic pharmaceutical preparations and substances for the treatment of incatment of the eye  Treatment of the eye  FILING DATE  INTL CLASS  REGISTRATION  REGISTRATION  STATUS			& <u>©</u>	5	
INVELTYS logo mumbers  MARK. (design plus words, letters &/or mumbers  MARK.  (B&W Eye (B&W E			===	Ď.	- 5
INVELTYS logo mumbers  MARK:  (B&W Eye  B&W Eye  Design)  iteral preparations and substances for the treatment of inflammation and pair, pharmaceutical preparations and substances for the treatment of ogtical and ocular diseases and disorders, topical ophthalmic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations and substances for the treatment of atment of the eye  anneal of the eye  PRINCIPATE  NUMBER  NUMBE			ನ 🖭	Ĕ	
INVELTYS logo mumbers  MARK (design plus words, letters &/or mumbers  MARK (B&W Eye (B&W Eye Design)  al preparations and substances for the treatment of inflammation and pain pharmaceutical preparations and substances for the treatment of incal and ocular diseases and disorders, topical ophthalmic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations in opical ophthalmic pharmaceutical preparations for postment of the eye  THEOREM AND THE ACTUALS REGISTRATION REGISTRATION  STATUS			₽Ç	7	
Type: TradeMark (design plus words; letters &/or Mark: (B&W Eye (B&W Eye mumbers))  Mark: (B&W Eye (B&W Eye Design))  preparations and substances for the treatment of inflammation and pair; pharmaceurcal preparations and substances for the treatment of all and ocular diseases and disorders; topical ophthalime pharmaceutical preparations; topical ophthalime pharmaceutical preparations for post-cart of the eye  The eye of the treatment of inflammation and pair; pharmaceutical preparations for post-cart of the eye  The eye of the treatment of the treatment of the treatment of the eye of the eye of the treatment of preparations for post-cart of the eye  The eye of the treatment of the treatment of the treatment of the eye of the eye of the treatment of the eye of the eye of the eye of the eye of the treatment of the eye of the e			≣ ₩	<u> </u>	
TYPE: TRADEMARK (design plus words, letters & for MARK:  (B&W Eye			¥ 2	ರ	
PRESENTABLE ARK (design plus words letters &/or MARK: (B&W Eye (B)))))))))))))))))))))	Y		Z ==	75	
PE: TRADEMARK (design plus words, letters & for mumbers    MARK   MARK   MARK   MARK   (B&W Eye			¥. ₹	덫	· · · · · · · · · · · · · · · · · · ·
TRADEMARK (design plus words, letters &/or MARK (B&W Eye (B&W Eye (B&W Eye (B&W Eye)))  thous and substances for the treatment of inflammation and pain, pharmaceutical preparations and substances for the treatment of cular diseases and disorders, topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-c-cyc  FILING DATE NTLCLASS REGISTRATION REGISTRATION STATES			5 ₹	₹	
TRADEMARK (design plus words, letters & for mumbers  MARK:  (B&W Eye (B&W E			ా దై	መ	•
TRADEMARK (design plus words letters & MARK:    MARK: (B&W Eye			\$ ₩	2	
TRADEMARK (design plus words, letters &/or MARK: (B&W Eye B&W Eye MARK: (B&W Eye B&W Eye))  and substances for the treatment of inflammation and pair, pharmaceutical preparations and substances for the treatment of diseases and disorders, topical ophthalmic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations ophthalmic pharmaceutical preparations for post-  BULING DATE BYTH CLASS REGISTRATION REGISTRATION STATES		· · · · · · · · · · · · · · · · · · ·	രട	ъ.	<b>=</b>
INVELTYS logo mbers  MARK: (design plus words, letters & for MARK: (B&W Eye B&W Eye)  In substances for the treatment of inflammation and pain, pharmaceutical preparations and substances for the treatment of secases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-seases and disorders; topical ophthalmic pharmaceutical preparations.  MARK: (B&W Eye Design)  Design)  STATUS  STATUS  STATUS			😩	8	- <b>8</b>
ADEMARK: design plus words; letters & for the treatment of inflammation and pair; pharmaceutical preparations and substances for the treatment of inflammation and pair; pharmaceutical preparations and substances for the treatment of assess and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-asses and disorders.  ADEMARK: design plus words; letters & for the Eye (B&W Eye)  Design)  Substances for the treatment of the treatment of assess and disorders; topical ophthalmic pharmaceutical preparations for post-assess and disorders; topical ophthalmic pharmaceutical preparations for post-assess and disorders; topical ophthalmic pharmaceutical preparations for post-assess and disorders; topical ophthalmic pharmaceutical preparations and substances for the treatment of assess and disorders; topical ophthalmic pharmaceutical preparations and substances for the treatment of assess and disorders; topical ophthalmic pharmaceutical preparations and substances for the treatment of assess and disorders; topical ophthalmic pharmaceutical preparations for post-assess and disorders; topical ophthalmic pharmaceutical preparations.  BEGISTRATION REGISTRATION STATUS		<u></u>	8	₽.	- <b>8</b> - ₩
INVELTYS logo  MARK  (B&W Eye  Besign)  the treatment of inflammation and pair, pharmaceutical preparations and substances for the treatment of inflammation and pair, pharmaceutical preparations and substances for the treatment of zero and disorders, topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-  TO DATE  NOTE CLASS  REGISTRATION  REGISTRATION  BATE  STATES		<b>∞</b>	2	ā	_ <b>©</b> 🏂
EMARK (design plus words, letters &/or MARK: (B&W Eye (Borders, topical ophthalmic pharmaceutical preparations and substances for the treatment of and disorders, topical ophthalmic pharmaceutical preparations topical ophthalmic pharmaceutical preparations for post-			Ą	ġ.	∽ ∪
MARK (design plus words letters & MARK:    MARK   MARK   MARK   MARK   (B&W Eye			23	<b>#</b>	四
ARK (design plus words, letters &/or MARK (B&W Eye B&W Eye B&W Eye)  ces for the treatment of inflammation and pairt pharmaceutical preparations and substances for the treatment of inflammation and pairt pharmaceutical preparations and substances for the treatment of inflammaceutical preparations; topical ophthalmic pharmaceutical preparations for post-  Design De			₩.	<b>5</b>	
MARK:  (B&W Eye  Body)  Stor the treatment of inflammation and pain pharmacentical preparations and substances for the treatment of pharmacentical preparations, topical ophthalinic pharmacentical preparations, topical ophthalinic pharmacentical preparations for post- isonders, topical ophthalinic pharmacentical preparations and substances for the treatment of the treatment of the treatment of the preparations and substances for the treatment of the treatment of the treatment of the treatment of the pharmacentical preparations for post- isonders, topical ophthalinic pharmacentical preparations for post- isonders				8	2
Or the treatment of inflammation and pain; pharmaceutical preparations and substances for the treatment of pharmaceutical preparations; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-		· -	7	vs.	4
MARK:  (B&W Eye  B&W Eye  Compared of inflammation and pain, pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations; topical ophthalinic pharmacentical preparations topical ophthalinic pharmacentical preparations for post-  (Compared to find a pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations for post-  (Compared to find a pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations for post-  (Compared to find a pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations for post-  (Compared to find a pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations for post-  (Compared to find a pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations for post-  (Compared to find a pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations for post-  (Compared to find a pharmacentical preparations and substances for the treatment of dens, topical ophthalinic pharmacentical preparations.)			9	8,	
esign plus words: letters &/or MARK: (B&W Eye B&W Eye B&W Eye)  the treatment of inflammation and pain: plus maceutical preparations and substances for the treatment of the treatment of preparations; topical ophthalinic pharmaceutical preparations topical ophthalinic pharmaceutical preparations for post-  The Class REGISTRATION REGISTRATION STATES			<u>o</u> .		<u>c</u> .
INTLCLASS  REGISTRATION  MARK:  MARK:  MARK:  MARK:  (B&W Eye  (B&		··············		₹	Š,
mplus words; letters & for MARK:  (B&W Eye (B&W Eye (B&W Eye (B&W)))  cattractif of inflammation and pair; pharmaceutical preparations and substances for the treatment of topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-  [NTL CLASS   REGISTRATION   REGISTRATION   STATUS					υīs
INVELTYS logo  MARK  (B&W Eye  Design)  timent of inflammation and pair, pharmaceutical preparations and substances for the treatment of pical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-  pical ophthalmic pharmaceutical preparations and substances for the treatment of pical ophthalmic pharmaceutical preparations for post-  pical ophthalmic pharmaceutical preparations and substances for the treatment of pical ophthalmic pharmaceutical preparations for post-  pical ophthalmic pharmaceutical preparations.			5	Ø	
MARK:  MARK:  (B&W Eye  Both Eye)  Incut of inflammation and pain, pharmaceutical preparations and substances for the treatment of adiophthalmic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations of pharmaceutical preparations for post-  RETE CLASS  HEGISTRATION  REGISTRATION  REGISTRATION  STATUS			₩.	<b>=</b>	
MARK:  MARK:  (B&W Eye  (B&W Eye  (B&W)  (Cophthalmic pharmaceutical preparations and substances for the treatment of implications for posting the parations of posting the parations for posting the paration of paratic pharmaceutical preparations for posting the paratic pharmaceutical preparations for posting the paratic pharmaceutical preparations for posting the paratic pharmaceutic pharmaceutic preparations for posting the paratic pharmaceutic preparations for posting the paratic pharmaceutic pharmaceuti			83	Ħ	8
ords, letters &/or  MARK  (B&W Eye  Design)  of inflammation and past; pharmaceutical preparations and substances for the treatment of phthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-  TLCLASS  REGISTRATION  REGISTRATION  REGISTRATION  PATE  INVELTYS logo  (B&W Eye  Design)  Design  Des	7	·	_	Ĕ	
MARK: (B&W Eye B&W Eye Bullanmation and pain, plurmaccutical preparations and substances for the treatment of thhalmic plurmaccutical preparations, topical ophilialinic pharmaceutical preparations for post-parations. The state of the preparations for post-parations for post-parations for post-parations.  1. Class REGISTRATION REGISTRATION STATES			Ť	<b>o</b>	9
MARK:  MARK:  (B&W Eye  (B&W Eye  (B&W)  (B&			<b>E</b>	<u> </u>	Ç.
INVELTYS logo MARK:  (B&W Eye Design)  Immination and pain; pharmaceutical preparations and substances for the treatment of limic pharmaceutical preparations; topical ophthalimic pharmaceutical preparations for post-  BEGISTRATION REGISTRATION STATES	<b>.</b>	. I .	- 5	₩	*
MARK:  (B&W Eye  Design)  mutation and pair, pharmaceutical preparations and substances for the treatment of the pharmaceutical preparations, topical ophthalmic pharmaceutical preparations for post-  ASS  REGISTRATION  REGISTRATION  DATE  INVELTYS logo  (B&W Eye  Design)  Design  Design  Design  REGISTRATION  STATUS	₩#	₩ *	=	5	
markion and pain; pharmaceutical preparations and substances for the treatment of pharmaceutical preparations and substances for the treatment of pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-		·	₩.	3	- 6
MARK:  (B&W Eye  Besign)  ation and pair pharmaceutical preparations and substances for the treatment of that runceutical preparations; topical ophthelimic pharmaceutical preparations for post-  HEGISTRATION  REGISTRATION  REG	· ·		73	\	22
MARK  MARK  (B&W Eye  Design)  for and pair, pharmaceutical preparations and substances for the treatment of actuaceutical preparations; topical ophthalmic pharmaceutical preparations for post-  MEGISTRATION  REGISTRATION  REGISTRATION  PATE  INVELTYS logo  Design)  Design)  STATUS		<b>*</b>	- <del>-</del>	<u> </u>	- >∞
MARK:  MARK:  (B&W Eye  Besign)  In and past, pharmaceutical preparations and substances for the treatment of maceutical preparations: topical ophthalmic pharmaceutical preparations for post-  MEGISTRATION  REGISTRATION  BY  STATUS  STATUS			5	<u>ō</u> `	*
MARK: (B&W Eye  Besign)  and pain, pharmaccutical preparations and substances for the treatment of accutical preparations, topical ophthalmic pharmaccutical preparations for post-  BEGISTRATION REGISTRATION STATUS  BATE		₩ <b>/</b>	#	5	
MARK  (B&W Eye  Design)  d pairt pharmaceutical preparations and substances for the treatment of entical preparations; topical ophthalmic pharmaceutical preparations for post-  GEGSTRATION  REGISTRATION  PATE  INVELTYS logo  B&W Eye  Design)  STATUS		₩ <b>**</b> **	ত	₩	
MARK: (B&W Eye B&W Eye Design) pain, pharmaceutical preparations and substances for the treatment of tical preparations, topical ophthalimic pharmaceutical preparations for post- BEGISTRATION REGISTRATION STATUS DATE		<b>~</b>		<b>C</b>	
MARK:  (B&W Eye (B&W Eye (B&W Eye (B&W) (B		- 1 m	₩.	<u> </u>	
MARK: (B&W Eye  Design)  pharmaceutical preparations and substances for the treatment of preparations; topical ophthelimic pharmaceutical preparations for post-  PATES  PATES  PATES			2	5	
MARK: (B&W Eye B&W Eye Design) harmacentical preparations and substances for the treatment of reparations, topical ophthalinic pharmacentical preparations for post-reparation.  STRATION REGISTRATION STATES			∵ .	• •	
MARK:  (B&W Eye (B&W		<b>** 1 1 1</b> 1	7	≌	
MARK: (B&W Eye  Besign)  maccurcal preparations and substances for the treatment of trations: topical ophthalmic pharmaccutical preparations for post- trations.  ATION REGISTRATION  STATUS			<b>Z</b>	2	
MARK (B&W Eye Design) accutical preparations and substances for the treatment of thoms, topical ophthalmic pharmaceutical preparations for post- thom REGISTRATION STATES	***		8	3	
MARK: (B&W Eye (B&W Eye )) cut-cal preparations and substances for the treatment of ones, topical ophthalmic pharmaceutical preparations for post-	- A		₽.	ಕ	
ARK:  (B&W Eye (B&W Eye Design)  Itical preparations and substances for the treatment of s. topical ophthalmic pharmaceutical preparations for post- s. topical ophthalmic pharmaceutical preparations for post- S. REGISTRATION STATUS			<b>Ξ</b>	₽	8
INVELTYS logo  IX: (B&W Eye  Design)  All preparations and substances for the treatment of topical ophthelimic pharmaceutical preparations for post- topical ophthelimic pharmaceutical pharma	~~		, co	₽	2
INVELTYS logo  : (B&W Eye  Design)    preparations and substances for the treatment of pical ophthalinic pharmaceutical preparations for post-  REGISTRATION  STATUS			8	మ	*
INVELTYS logo (B&W Eye Design) reparations and substances for the treatment of call ophthelimic pharmaceutical preparations for post- REGISTRATION STATES			Ð.	-	
INVELTYS logo (B&W Eye (B&W Eye Design) parations and substances for the treatment of d ophthalmic pharmaceutical preparations for post- BEGISTRATION STATUS			Ç,	7	
INVELTYS logo (B&W Eye Design) nations and substances for the treatment of sphilhalmic pharmaceutical preparations for post- parts  REGISTRATION STATUS				<b>T</b>	
INVELTYS logo (B&W Eye Design) thons and substances for the treatment of hillsalimic pharmaceutical preparations for post- EGISTRATION STATES			8	<del>5</del>	
INVELTYS logo (B&W Eye Design) ons and substances for the treatment of halimic pharmaceutical preparations for post- stration JSTRATION STATUS			- ₹	₽	
INVELTYS logo (B&W Eye Design) s and substances for the treatment of limic pharmaceutical preparations for post- limic pharmaceutical pharmaceutical pharm			#	9	
INVELTYS logo (B&W Eye Design) and substances for the treatment of the pharmaceutical preparations for post- the pharmaceutical preparations for pharmaceu	<b>5</b> 7		=	55	
INVELTYS logo (B&W Eye Design) d substances for the treatment of pharmaceutical preparations for post- pharmaceutical preparations for post-			₩.	8	
INVELTYS logo (B&W Eye Design) substances for the treatment of sharmaceutical preparations for post-	20		~ ~	₫	
INVELTYS logo (B&W Eye Design) bisances for the treatment of armaceutical preparations for post-	~ 4		- ₩	2	
INVELTYS logo (B&W Eye Design)  trances for the treatment of maceutical preparations for post-			==	Ŏ.	
INVELTYS logo (B&W Eye Design) mees for the treatment of accument preparations for post-			₹.	Š	
INVELTYS logo (B&W Eye Design) res for the treatment of etuical preparations for post-			ನ	₽	
INVELTYS logo (B&W Eye Design) s for the treatment of tical preparations for postitical preparations.			2	ď	
INVELTYS logo (B&W Eye Design) or the treatment of rad preparations for post-			₩.	<i>∕</i> a →	
NVELTYS logo B&W Eye Design) the treatment of I preparations for post- STATUS			- 2	≌ 🛶	<b>~</b> —
VELTYS logo &W Eye sign) ac treatment of reparations for post- STATUS				= <b>%</b>	W Z
TELTYS logo IW Eye ign) iteratment of parations for post- status			75	ማ 🕉	<b>%</b> ~
ELTYS logo N Eye m) caument of trations for post- status			Ţ,	≕ 01 <b>0</b> °	
Eye threat of thoms for post-			<b>#</b>	8 🚡	< ≅
TYS logo Eye nem of ons for post-			₩.	8-	_ ~
YS logo Fe Int of Is for post-			2	ត .	<u> </u>
S logo of for post-			ಶ	2	~ <
logo r post-			ප	0	
ogo post-			Ä	<del>~~</del>	_
St.			72		
' '			- 2		Ğ
4					

(United States)	KTM011/US	
	88/018,617	
	28-Jun-2018	
	005	
	5,968,321	
	21-Jan-2020	
	REGISTERED	

KTM012/US (United States)	OUR REF NO			DESCRIPTION:	FAMILY:
2/US States)	FNO			PTION:	<b>.</b>
88/018,623	APPL'N NO. A		ophthalmological and ocular surgical treatment of the eye	Pharmaceutical preparatio	VIMOIS THE
28-Jun-2018	FILING DATE		ar diseases and disorders; ve	us and substances for the t	numbers)
005	INTT CLASS		юрісаі орипаліне риагна	reatment of inflammation a	inders)
5,968,322	REGISTRATION	Û	centical preparations, top	ınd pain, pharmaceutical j	MARK:
21-Jan-2020	REGISTRATION		ophthalmological and ocular diseases and disorders; topical ophthalmic pharmacentical preparations, topical ophthalmic pharmacentical preparations for post- surgical treatment of the eye	Design)  Pharmaceutical preparations and substances for the treatment of inflammation and pain, pharmaceutical preparations and substances for the treatment of	
REGISTERED	STATES		cal preparations for post-	Design) for the treatment of	Logo (Green Eve

	KALA FAMILY: DESCRIPTION
	2 7 -
	Z
	₩ 🛩
	<b>—</b> ••
	<b>_</b>
	<b>Q</b>
	2
w o	т 🛶
⊕ × <del>5</del>	= ^
00 ☴	
ophthalmological and ocular surgical treatment of the eye	CTM013
₽ ₽	Ş — <u>—</u>
	X •
ਨ <u>੧</u>	=
20	<u>໘</u>
	స్త
$\Omega$	<del></del>
# -	TYPE:
o ≌	2 2
ాద	Š 🙀
<b>₽</b> o	8 <del></del>
ര മ	₽ ••
<b>9</b> =	2
രെ≌	<b>5</b>
<b>.</b>	₽
- Z	₩ ==
Q	~ ~
- 2	골 🏲
S.	ğ U
<u></u>	# 3
₩ 👨	TRADEMARK (design) and substances for the treat
	\$ >>
	86 70
υ <u>ν</u>	≂ ⊼
<b>—</b>	¥
6	= #
	<b>ი</b> ⊻
	<del></del> 079
5	7 E
∵ 'ਦ	2
0	8
— <u>—</u>	Ω
•	=
Ξ.	<u> </u>
55	2
- E	₩.
	5
- 5	min
# 91	HIIHA
nc pha	
nc pharn	юпвини
tic pharma	a nonamu
не рһатпас	инпацоп ан
nc pharmaceu	unnation and
nc pharmaceution	mmanon and pa
нс ріатпіасенніса	unnation and pair
nc pharmaceutical	unmation and pain.
нс pharmaceutical pr	mmanon and pain, p
nc pharmaceutical prep	unmation and pain, phe
не рһагшасеніса! ргера	mmanon and pain, phan
nic pharmaceutical prepara	munation and pain, pharm
nic pharmaceutical preparati	mmation and pain, pharmac
nic pharmaceutical preparation	M munation and pain, pharmacet
ophthalmological and ocular diseases and disorders, topical ophthalmic pharmaceutical preparations sugical treatment of the eye	MAI mmation and pain, pharmaccuti
nic pharmaceutical preparations, t	MAR! munation and pain, pharmaceutic:
nic pharmaceutical preparations, top	MARK:
nic pharmaceutical preparations, topu	MARK: ununation and pain, pharmaccutical pr
nic pharmaceutical preparations, topica	MARK munation and pain, pharmaceutical pref
nic pharmaceutical preparations, topical c	MARK:
tic pharmaceutical preparations, topical op	MARK: ummation and pain, pharmaccutical prepara
tic pharmaceutical preparations, topical ophi	MARK: munation and pain, pharmaceutical preparati
nic pharmaceutical preparations, topical ophth	MARK:
nic pharmaceutical preparations, topical ophthali	MARK: munauon and pain, pharmaceutical preparations
nic pharmaceutical preparations, topical ophthatin	MARK: ununation and pain, pharmaceutical preparations as
nic pharmaceutical preparations, topical ophthalmic	MARK: ummation and pain, pharmaceutical preparations ark
nic pharmaceutical preparations; topical ophthalmic p	MARK: imination and pain, pharmaceutical preparations and t
nic pharmaceutical preparations, topical ophthalime plu	MARK:
nic pharmaceutical preparations; topical ophthalmic phar	MARK: ununation and pain, pharmaccutical preparations and subs
ne pharmaceutical preparations, topical ophthalmic pharm	MARK munation and pain, pharmaceutical preparations and substa
nic pharmaceutical preparations, topical ophthalimic pharmac	MARK: ummation and pain, pharmaccutical preparations and substan
nic pharmaceutical preparations; topical ophthalmic pharmacei	MARK: ununauon and pain, pharmaccutical preparations and substance
nic pharmaceutical preparations, topical ophthalmic pharmaceut	MARK: munation and pain, pharmaceutical preparations and substances
nic pharmaceutical preparations, topical ophthalmic pharmaceutic	MARK: ununation and pain, pharmaceutical preparations and substances fo
nic pharmaceutical preparations, topical ophthalmic pharmaceutical	MARK.  D  mination and pain, pharmaceutical preparations and substances for
nic pharmaceutical preparations, topical ophthalinic pharmaceutical p	MARK De unmation and pain, pharmaccutical preparations and substances for th
ne pharmaceutical preparations; topical ophthalmic pharmaceutical pre	V &  LEX  Description of the state of the st
nic pharmaceutical preparations, topical ophthalinic pharmaceutical prepa	V &  NRK Des  Lical preparations and substances for the
nic pharmaceutical preparations, topical ophthalmic pharmaceutical prepar	MARK:  Design manation and pain, pharmaceutical preparations and substances for the trea
nic pharmaceutical preparations; topical ophthalmic pharmaceutical preparati	V &  NRK Des  Lical preparations and substances for the
nic pharmaceutical preparations; topical ophthalmic pharmaceutical preparatio	V & B&V  NRK Design tical preparations and substances for the treatment.
nic pharmaceutical preparations, topical ophthalinic pharmaceutical preparations	V & B&V  NRK Design tical preparations and substances for the treatment.
nic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations f	V & B&V  NRK Design tical preparations and substances for the treatment.
nic pharmaceutical preparations, topical ophthalinic pharmaceutical preparations for	V &  NRK Des  Lical preparations and substances for the
nic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for p	V & B&V  NRK Design tical preparations and substances for the treatment.
nic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations for por	V & B&V  NRK Design tical preparations and substances for the treatment.
nic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations for post-	V & B&V  NRK Design tical preparations and substances for the treatment.
nic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-	V & B&V  NRK Design tical preparations and substances for the treatment.
thic pharmaceutical preparations: topical ophthalmic pharmaceutical preparations for post-	V & B&V  NRK Design tical preparations and substances for the treatment.
nic pharmaceutical preparations, topical ophthalmic pharmaceutical preparations for post-	V & B&V  NRK Design tical preparations and substances for the treatment.

4P1. V.NO. FILING DATE 88/018,632 28-Jun-2018		FILING DATE 28-Jun-2018	KTM014/US (United States)	OUR REF NO	
	######################################	HEING DATE INT'L CLASS 28-Jun-2018 005 5	88/018,632	APPL'N NO.	
	DALIT CITYAS	Vs.	28-Jun-2018	FILING DATE	
REGISTRATION REGISTRATION DATE 5,968,324 21-Jan-2020	REGISTRATION DATE 21-Jan-2020		REGISTERED	STATUS	

KALA FAMILY:

KTM014

TYPE:

TRADEMARK (design)

MARK:

V & Green Eye

				·
(United States)	$\mathbf{z}$			
ij	$\exists$	OUR REF NO		
듄.	≦	· · · · · ·		
<u>0</u>	2	<b>2</b>		
Sts	3/			
ਰਿ	2			
S)	•	<b>.</b>		
	00			
	8			
	$\Xi$			
	88/018,626	APPL'N NO		
	22			
	٠,	w <del>y</del>		
	28-Jun-2018	FILING DATE		
	۲ٍ			
	Ħ			
	-2			
	$\Xi$			
	×			
			- Z	
		<b>7</b>		
	0	₩.		
	005	<b></b>		
	٠,	₩.		
		INT'L CLASS		
		7		
	5,968,323			
	96	- Z		
	œ	<b>.</b>		
	32	<b>***</b>		
	w	24		
		ÓĦ		
		REGISTRATIO		
		- P		
	2			
	$\overline{\mathcal{T}}$			
	21-Jan-2020	REGISTRATION DATE		
	$\Sigma$	Ω		
	ĕ	- 7		
	20			
	ы			
	REGISTEREI			
	Ġ			ø
	$\mathbf{S}$			
	H	STATUS		ø
	Ħ			
	田			
	)			
		KKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKKK		
		<b> </b>		

(United States)	×	OUR REF NO				DEX KIT HON:
Jn	Ξ					F
뎐.	⋚	· · ·				ř
<u> </u>	);	<b>₩</b> ₩				Z
Ĕ	KTM015/US	-				Ī
es	S					
_		•				þ
						••
			0	α.	ωŋ.	٠,
			ਨੂੰ	<u> </u>	<b>,</b>	H
			181	₩'	₫.	Ξ
	88	- 5	atı	=	9	30
	Ò		011	ā	S	Ξ
	$\ddot{c}$		s.	ឮ	ች.	100
	88/062,537	APPL'N NO.	ĭ.	₩.	5	Ξ
	7		юc	₫,	ġ.	ë
			Ť	6	o.	23
			•	₹.	S	311
			£ 3	<u> </u>	₽.	9
			à	g .	Ď.	3
		- B	Te:	3	물	3
	2-	₩₩	a	2	8	BS
	Αu		<u>a</u>	5	5	30
1	jo	- P	=	3	ģ	1311
	2-Aug-2018	FILING DATE	э£ 1	B	Ħ	8
	∞	-	æ	<u>.</u>	2	3 1
			9	5	710	Ξ
			Ģ	3	ğ	Е
			õ	Ĕ.	2	130
			Õ.	ń	<u></u>	2
		-	ш.	5	3	H
			β	5	Ĩ	Ξ
			B	2	2	2
	005		ılırı	<u> </u>	ş	Ξ
		INT'I CLASS	reparations for post-surgical treatment of the eye; topical ophthalmic pharmaceutical preparations	phthalmic phirmacentical preparations and substances, topical orbibalmic pharmacentical prepara	symptoms of day eye disease, pharmaceutical preparations and substances for the treatment of ophili	Frathaceulical preparations and substances for the freatment of inflammation and pain pharmaceu
			ph	2	ក្ត	Ξ
			ап	Ē	S D	3
			1131	<u> </u>	Ξ.	110
			ğ	3	ಕ	<u>an</u>
			E	Z	Ħ	0
		REGISTRATIC	₽.	8	ä	HE
			9	<b>#</b> .	<del>=</del>	_
		22	20	22	Ξ.	113
		0 70	161	9	Σ,	Ξ
			ō,	ğ,	8	90
		<b></b>	S	2	Ē	Ξ
			OT.	5	≌.	S
			Ħ	ñ	ਛ	<u> </u>
			Ĭ	Ž,	9	G
		72	cat	2	Ž.	ă
			<b>13</b>	ğ	<u>.</u>	118
			Ħ	2	雹	H
		ISTR/ DATI	of	5	8	2
			dı.	•	로	ಕ
		REGISTRATIO DATE	<b>.</b>	9	Ħ	HES
		<b></b>	Š	ā	3	35
			OÍ.	=	Š	Ĭ
			nt of dryness of the eye	nons and substances, topical ophibalinic pharmaceutic.	almological and ocular diseases and disorders, injectabl	preparations and substances for the relief of signs ar
			co Co	=	22	8
			ရိ		å	2
				ក	S	್ಷ
	Æ			9	ď.	£
	Ï			8	ž.	2
	$\frac{1}{2}$				=	2
	ALLOWED			2	<u></u>	SIS
	J			7	ž	BS
				₽.	E.	1
						O
		<i>VIIIIIII</i>	1000000		00000	

2 <b>x</b>		<b>5</b> 7 7
		S 3 2
(United States)	OUR REF. NO	FAMILY: DESCRIPTION:
St: 6/1		
us ates		□
<u>o</u>		9
		•
		222 <b>7</b>
		K1M016 TYPE: Pharmaceutical preparatio symptoms of dry eye disea ophthalmic pharmaceutica preparations for post-surgi
00	APPL'N NO.	
8/0		
62,		<u> </u>
88/062,546		
٥,		
		2 <del>5</del> 8 8
		# # # E
2-		
Αu		
g-2		
2-Aug-2018		[2 E 5 % \$
∞	FILING BATE	S 5 5 7
		Se de la care
		in in the color of the color of the mark) and substances for the treatment of pharmaceutical preparations and eparations and substances; topical treatment of the eye, topical ophic
0	INT'L CLASS	
005		
	<b>**</b>	
	REGISTRATIC NO.	
	<b>2</b>	an Har
	2	MARK: cutical lithalm tration
	- 7	用
		E S E
	REGISTRATION DATE	1
		E E E S
		K I MO16 TYPE: TRADEMARIS (Guaracter mark)  Pharmaceutical preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the symptoms of dry eye disease; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye
		E
A		MARK: LUXTREON  KIMUI6 1876: IRADEMARK (character mark)  Pharmaceutical preparations and substances for the treatment of inflamination and pain; pharmaceutical preparations and substances for the relief of signs and symptoms of dry eye disease; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; injectable ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye.
ABANDONED		
H		B 7 5 <b>x</b>
ğ	STATUS	
D		
		PE
	VIIIIIII	

		<b>****</b>	
Ħ.	KTM017/US	OUR REF. NO	KALA FAMILY: DESCRIPTION
(United States)	Ξ	75	95>
S	=		= 5
ate	5		<b>-</b>
Š	<b>J</b> 2	8	5
			7
			KTM017  Pharmaceutical symptoms of dophthalmic plus preparations for
	00	APPL'N NO.	
	88/062,540	-	
	26		8
	3,5		<u> </u>
	6	8	
			¥ 60 €
			TYPE: preparati y eye dis rmaceutic r post-sur
			65 5 8 5 ···
			- 3 - B - 4
	K)		
	,-\		
	Bn		
	<u>-</u> -2		
	2-Aug-2018	FILING BATE	
	00		5 2 T 5 X
			왕 등 <u>하</u> 글 (오)
_			KTM017 TYPE: TRADEMARK (character mark)  REYALBIS  Pharmaceutical preparations and substances for the treatment of inflammation and pain, pharmaceutical preparations and substances for the relief of signs an symptoms of dry eye disease, pharmaceutical preparations and substances to the treatment of ophthalmological and ocular diseases and disorders, injectable ophthalmic pharmaceutical preparations and substances, topical ophthalmic pharmaceutical preparations for post-sugical treatment of the eye, topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye.
			5 S S E
	0	INT'L CLASS	
	005	_	
			5 <b>5 6 6</b>
			# <del>1</del> 2
			8 = = =
			<u> </u>
			<b>9</b>
		65	
		REGISTRATION	F-E-S-E
		<b>9</b>	MARK: eutical hthalm hthalm urations
			F 2 2 2
			5 E E E
		REGISTRATION DATE	
			F 2 2 5
			¥668 B
		BATE	
			# # E B #
			8 5 5 8
			⊕ <b>⊈</b> % Ø
			[c≢∄5
			REYALBIS cal preparations and substances for the relief of signs almological and ocular diseases and disorders injecta tions and substances; topical ophthalmic pharmaceutic or the treatment of dryness of the eye
			5 5 6 F
	$\geq$		
	F		
	9		# <u> </u>
	ALLOWED	STATUS	8 <b>2 3</b>
	Ü		
			G 22 % <b>7</b> 2
			Control of the Contro
			KTM017 TYPE: TRADEMARK (character mark)  REYALBIS  Pharmaceutical preparations and substances for the treatment of inflammation and pain, pharmaceutical preparations and substances for the relief of signs and symptoms of day eye disease, pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders, injectable ophthalmic pharmaceutical preparations and substances, topical ophthalmic pharmaceutical preparations and substances topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye, topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye.

	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		30000
(C ×		□ 73	7
		83	KALA
ed 10		2 <b>=</b>	
KTM018/US (United States		FAMILY: DESCRIPT	
KTM018/US (United States)	OUR REF. NO	<b>=</b>	
( ا		FAMILY: DESCRIPTION	
		**	
		252 ;	Ą
		s gs :	
88		<b>Ξ</b> ∄″ β	5
88/066,300	APPL'N NO	Class 5 Phar nanoparticles Class 10 Pha	KTM018
6,3		∄ ∄	
8		<u> </u>	-
		É, F	Ĭ
		<u> </u>	TYPE:
		g ğ	
		e F	H
6.	FILING DATE	RClass 5. Pharmaceutical products, namely, drug delivery agents in the form of sterile preserved op nanoparticles. Class 10. Pharmaceutical products, namely, a drug delivery system comprising mucus-penetrating.	TRADEMARK (character mark)
6-Aug-2018			밁
-2-B		<u> </u>	Ž
01.		7 î	Ŕ
_ ∞		- H	<u></u>
		f A	12
		e I	12
		ž ž	គ
		7 #g	HIA
2	INT'I CLASS	7 E	Z
005, 010		g =	
010		8 🛱	
_		<b>∄</b> ₽	
		e ž	
5,			
95			
5,951,075	REGISTRAT	<del>i</del> ž	
75		<u>5</u> 9	
		<u> </u>	
		hithal	
		y E ^	
3		E &	
Į-D		r ë	
31-Dec-2019		ARK: FXIVE E LLE  whalmic suspension comprising mucus-penetrating  manoparticles	
201		Ö	
19		8	
		₫	
	<b>//9</b>	<u> </u>	
		Æ	
		<b>3</b>	
		# )	
R		曹星	
EG		5 <b>.</b>	Y
REGISTERED			
Ħ		165	
E			
-			
			_

KALA FAMILY:  KATM019 TYPE: TRADEMARK (design plus words, letters  LYSUVIS logo (Color Eye Shape)  Pharmaceutical preparations and substances for the treatment of ophthalmological and octular diseases and disorders; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of day eye disease  Pharmaceutical preparations for the relief of the signs and symptoms of day eye disease  RTM019/US  REGISTRATION  REGISTRATION  PATE  OUnited States)  REGISTERED  REGISTERED							8	<b>7</b>
KTM019 TVPE: TRADEMARK (design plus words, letters  &/or numbers  WARK:  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders: topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease preparations topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease  **APPLYNO**  **APPLYNO**  **PRINGEDATE**  **INTECLASS**  **REGISTRATION**  **BATTECTASS**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **BATTECTASS**  **REGISTRATION**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **REGIST	Jnit.						Š	<u> </u>
KTM019 TVPE: TRADEMARK (design plus words, letters  &/or numbers  WARK:  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders: topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease preparations topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease  **APPLYNO**  **APPLYNO**  **PRINGEDATE**  **INTECLASS**  **REGISTRATION**  **BATTECTASS**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **BATTECTASS**  **REGISTRATION**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **REGIST	1015 ed S						2	<u>&gt;</u>
KTM019 TVPE: TRADEMARK (design plus words, letters  &/or numbers  WARK:  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders: topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease preparations topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease  **APPLYNO**  **APPLYNO**  **PRINGEDATE**  **INTECLASS**  **REGISTRATION**  **BATTECTASS**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **BATTECTASS**  **REGISTRATION**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **BATTECTASS**  **REGISTRATION**  **REGIST	) State	*					7	ž
KTM019 TYPE: TRADEMARK (design plus words letters  &/or numbers  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease preparations topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease  **APPL'NO*** FILING BATE***  **NO*** NO*** REGISTRATION***  **PORTOR** OF THE NOTAGE ASS REGISTRATION**  **	8 0	ő					3	¥
RTM019 TYPE: TRADEMARK (design plus words letters  &/or numbers  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical oph preparations, topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease preparations.  ###################################							<b></b>	Ξ.
ncal oph								
ncal oph						3	<del>'U</del>	7
ncal oph						ecpa.	ham	
ncal oph	88/	-				Milit	73 23 24	S
ncal oph	708,					ĬIS,		3
ncal oph	726	Z				<u> </u>	<u> </u>	-
ncal oph						Cal.	Ç D	Ĭ
ncal oph						oph	rati	
ncal oph							SHC	<b>~</b> 1
ncal oph	27	2				景	E.	\$ 7
ncal oph	-No					pha	Sips	
ncal oph	v-2(					100	ži D	₹ ₹
ncal oph	)19					eu	SS	× Z
ncal oph						<u>E</u>	<u>6</u>	(des
ncal oph						pict	8	ğ
ncal oph			<b>8</b>			ara	rean	plus
ncal oph		-				10118	nen	# 6
ncal oph	005		<b>***</b>	**************************************		5	Ξ,	ids
ncal oph	•	7		8 *		He.	oph.	lett
ncal oph		*	* *			匵		ä
ncal oph			W			ော်	10H	
ncal oph	6,	-	<b>(***</b> )		<b>%</b>	F	318	
ncal oph	310,			8	(198	Si8	<u> </u>	
ncal oph	078	, 2		<b>8</b>	100	5 8	<u>б</u> .	
ncal oph		O 75	8			E S	zula.	
ncal oph		7				ΥЩ	Ġ.	≶
ncal oph						ion	seas	뽔
ncal oph	<u> </u>			889		 SO	33 43	
ncal oph	<u> </u>	7				ģ	g G	
ncal oph	ar-2	-9				S	ison	
ncal oph	021	4#				dis	ders	
ncal oph		7				case	S	
EYSUVIS logo (Color Eye Shape) opinimimic pinarmaceutical  STATUS  REGISTERED		9					)ica	
EYSUVIS logo (Color Eye Shape) uhalmic pharmaceutical  STATES REGISTERED							<u>9</u>	
olor Eye Shape) imic pharmaceutical  STATUS							Ē7	35
UVIS logo or Eye Shape) phurmacentical STATUS EGISTERED	7							≥ 5⁄2
IS logo Eye Shape) umaceutical  FATUS ISTERED	ΈG	ø						12
Shape) aceutical aceutical aceutical	TSE						HIN.	<b>7</b>
tical	ERI						<u>5</u>	25
	Œ							<b>.</b> 75
								•

KTM020 TYPE: TRADEMARK (design plus words, letters &/or mimbers EYSUVIS logo

DESCRIPTION: KALA FAMILY:

Pharmaceurical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease.

MARK

(B&W Eye Shape)

ス	<b>6</b>		
ð			
20/			
ğ			
<b>J</b> 2			
က	<u> </u>		
8	3		
708			
4			
ò	•		
27.			
Ż			
₹.			
201			
9			
$\cong$			
<u>,</u>		. 4	
	, an		
		$(I)_{-}$	
_			
6,3	-		
10,		• • • • • • • • • • • • • • • • • • •	
07	7		
9	65		
		<b></b>	
		7/1	
		V4	
30			
Ē			
Ē.			
200	<b>9</b> 2		
21	= =		
	<b>7</b> 5		
$\mathbb{Z}$			
EG			
$\mathbf{S}$			
园			
E			
U			
	************	4	
	KTM020/US 88/708,748 27-Nov-2019 005 6,310,079 30-Mar-2021 REGISTERED	O         APPL'N NO.         FILING DATE         INFLECTASS         REGISTRATION NO.         REGISTRATION DATE           88/708,748         27-Nov-2019         005         6,310,079         30-Mar-2021	APPLIA

$\sim$	T		= =
Un	T		ĦΣ
(United States)	<b>KTM021/US</b>	OUR REF. NO	KALA FAMILY: DESCRIPTION:
5	02		Z *
2	$\leq$	-	₹ ₹
g	$\mathbf{z}$		= 5
_			9 =
			: 5
			••
			о <del>т н.</del> _
			K I M021  Pharmaceutica preparations a ophthalmic ph
	88		
	/79		7 3 6 7 <b>7</b>
	ζ,		ph s iic
	88/797,027	APPL'N NO	
	7		I FFE: d prepara nd substa armaceut
			8 5 2
			<u> </u>
			P
	_		995.
	3-1		31 E
	eg.	<b>88</b>	
	5		
	13-Feb-2020	FILING DATE	
	_		d H S S
			<u> </u>
			and substances for the treatment topical ophthalmic pharmaceutic reparations and substances for the
			CS 1344 1
	_	INT'L CLASS	6 H S
	005		<u> </u>
	O	₩	ğ p g
			<b>₽</b> ₩₩
		<b>9</b>	<u> </u>
			N. I. M. 0.2.1 (A.F.E.: LEADEMACK) (character mark)  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular dispreparations and substances; topical ophthalmic pharmaceutical preparations and substances for ophthalmic pharmaceutical preparations and synglephinalmic pharmaceutical preparations and substances for temporal relief of the signs and synglephinalmic pharmaceutical preparations and substances for temporal relief of the signs and synglephinalmic pharmaceutical preparations and substances for temporal relief of the signs and synglephinalmic pharmaceutical preparations and substances for temporal relief of the signs and synglephinalmic pharmaceutical preparations.
			2, B 5
			and the
		REGISTRATIO	2 2 2
			163 EF
		W 2	S a o
		0 #	E 6 2
			MAR r disa for t yrup
			日 景楽 子
			KIM021 TITE: TRADEMARK (CHARGE HAIR)  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders, topical ophthalmic preparations and substances; topical ophthalmic pharmaceutical preparations and substances for the treatment of dryness of the eye or dry ophthalmic pharmaceutical preparations and substances for temporal relief of the signs and symptoms of dry eye disease or dry eye flares.
			5 7 8 8 C R
			25E
			286
			9 5 9
		2	_ 626 646
			186 28
			<u> </u>
		REGISTRATION DATE	6 6 5 5
			1 2 E S
			90E <b>-</b>
	$\triangleright$		RELFLAYRA thalmic pharmaceum ye or dry eye flares ye flares
	ALLOWED	STAILS	KIM021 THE TRADEMARK (CHARGET HARK)  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations and substances; topical ophthalmic pharmaceutical preparations and substances for the treatment of dry ness of the eye or dry eye flares topical ophthalmic pharmaceutical preparations and substances for temporal relief of the signs and symptoms of dry eye disease or dry eye flares.
	Ó		
	$\mathbb{Z}$		
	$\Box$		8 E C
	_		58
			¥ "
			별
			1

KTM022/US (United States	KALA FAMILY: DESCRIPTION: OUR REF. NO
lite Me	# SC
S   S	Z >
Stat 2	FA P3
KTM022/US (United States)	N IC
	9 2 F
	*
	6 m m
	bph 7
l ~	ilian TV
88/797,025	KTM022 TVPE: Pharmaceutical preparati preparations and substan ophthalmic pharmaceuti APPL'N NO
797	E Grand
, 25	than tall
\ \cdot	Die list
	PH CCI
	nic ati
	ons es: al p
	TR HE
13-	AI AI Par
Fe	Z HE H
J- <u>2</u>	Hai MA
13-Feb-2020	RADEMARK and substances topical ophthala reparations and substances.
	d sa de la constant d
	han the p pbs
	TRADEMARK (character mark) and substances for the treatment topical ophthalmic pharmaceutic preparations and substances for to
	er ica ina ces
	mark) iment of ophtha accutical prepar s for temporal re
	To the district th
05	of a
	ora sph
	Tree His
	line
	of 18
	the sing
	MA Sail and ocular dad substances for signs and syn REGISTRATH
	gns bat
	d s
	MARK: disease for the ympto
	Z Jan S
	ins in ses
	KTM022 TVPE: TRADEMARK (character mark)  MARK.  SPEDLYF  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations and substances for the treatment of the signs and symptoms of the eye or thy eye flares; topolar pharmaceutical preparations and substances for temporal relicf of the signs and symptoms of thy eye disease or dry eye flares  APPL'N NO PILING DATE INTLICIASS REGISTRATION REGISTRATION DATE
	id disorders; topace ment of dryness of dryness of dryness or dryness or ATTATION
	LE CY CO
	HO ISCA
	tse opi
	or cal
	dy the op
	SSE W
	SPEDLYF thalmic pharma ye or dry eye fl eye flares STAT
	ard:
<u> </u> AL	y S S P H
ALLOWED	LYF sharmace eye flan
ĕ	H Had
E	<b>7 3 2</b>
	. TO
	KTM022 TYPE: TRADEMARK (character mark)  MARK:  SPEDLYF  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations and substances for the treatment of dry ness of the eye or dry eye flares; topical ophthalmic pharmaceutical preparations and substances for the signs and symptoms of dry eye disease or dry eye flares; topical ophthalmic pharmaceutical preparations and substances for temporal relief of the signs and symptoms of dry eye disease or dry eye flares  APPLINIO PLENGBATE INTEGRATION REGISTRATION STATES
	21.

OF RREF. NO		DESCRIPTION:	KALA FAMILY:	KTM023/US (United States)	OUR REF. NO		DESCRIPTION:	KALA FAMILY:
APPL'N NO.	ргерагапоня; юрксаг орг	Pharmaceutical preparat	KTM024 TYPE:	90/126,591	ON N. TERN	preparations; topical opl	Pharmaceutical preparat	KTNI023 TYPE:
FILINGDATE	preparations; topical ophilialiniic pharmacentical preparations for the relief of the signs and symptoms of dry eye disease	Shape)  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders, topical ophthalmic pharmaceutical	TRADEMARK (design plus words, letters &/or numbers	08-20-2020	FILING DATE	preparations: topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease.	Shape)  Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders, topical ophthalmic pharmaceutical	TRADEMARK (design plus words, letters &/or numbers
INT'L CLASS	repairations for the relief of	e treatment of ophthalmol	gn plus words, letters	005	INT'L CLASS	reparations for the relief o	e treatment of ophthalmol	gn plus words, letters
RECISTRATION	If the signs and symptoms	ogical and ocular diseases	MARK:		REGISTRATION	If the signs and symptoms	ogical and ocular diseases	MARK:
ON REGISTRATION	ol diy eye disease.	; and disorders; topical of			REGISTRATION DATE	of dry eye disease	and disorders, topical or	
SHARIS		Shape) shthalmic pharmaceutical	EYSUVIS Updated logo (B&W Eye	ALLOWED	SHVIS	•	Shape)  bhhalmic pharmaceutical	EYSUVIS Updated logo (Color Eye

			(United States)
005	08-20-2020	90/126,587	KTM024/US

**RECORDED: 05/06/2021**